1,900 members and growing fast. Welcome everyone!

I want to make sure the content here actually serves you, so I'm opening it up: what do you want to see more of? Deeper compound breakdowns, protocol guides, research news, experience/log threads, vendor reviews, beginner resources, Q&A formats?

Drop it in the comments. I read everything and the most requested topics will drive what gets posted next.

Retatrutide is one of those compounds that gets thrown around in weight loss conversations like it's just "a stronger Tirzepatide."

It isn't.

Retatrutide is a triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, making it the most pharmacologically aggressive metabolic compound currently in development. Where Semaglutide hits one receptor and Tirzepatide hits two, Retatrutide hits three, and that third receptor, the glucagon receptor, is what separates it from everything that came before it.

This isn't a marginal upgrade. The mechanism is categorically different.

Interest in Retatrutide across the UK, Europe, and the broader EU peptide community has accelerated significantly, particularly among users who have plateaued on Semaglutide or Tirzepatide and are looking for the next step. But most people running it don't fully understand what the glucagon receptor is actually doing, and that gap in understanding is costing them results.

Let's fix that.

What It Actually Does

Retatrutide works by engaging three distinct hormone receptors simultaneously, each contributing a different layer to the metabolic effect:

GLP-1 (Glucagon-Like Peptide-1): Slows gastric emptying, suppresses appetite centrally via the hypothalamus, enhances insulin secretion, and blunts post-meal blood glucose spikes. This is the same pathway targeted by Semaglutide.

GIP (Glucose-Dependent Insulinotropic Polypeptide): Boosts insulin sensitivity, improves nutrient partitioning, and amplifies the appetite-suppressing signal already being driven by GLP-1. This is the second pathway Tirzepatide also engages.

Glucagon Receptor: Directly elevates energy expenditure and accelerates hepatic fat oxidation. This is the mechanism that separates Retatrutide from every predecessor. It drives thermogenesis and pushes fat burning well beyond what appetite suppression alone could ever produce.

Put simply: GLP-1 and GIP cut intake. Glucagon drives output. The result is a dual-sided caloric deficit that explains why Retatrutide's trial data looks the way it does.

Who It Is For

Ideal candidates:

• Individuals pursuing significant fat loss, particularly those carrying substantial excess weight
• Those who have plateaued or stalled on single or dual agonist protocols and need a more aggressive intervention
• People presenting with metabolic dysfunction including insulin resistance, dyslipidemia, or elevated visceral fat
• Experienced users well-acquainted with GLP-1 class compounds and their side effect profile

Not recommended for:

• Active pancreatitis or any documented history of severe pancreatitis
• Pregnancy or breastfeeding
• Individuals entirely new to peptides with zero prior GLP-1 exposure
• Those managing a history of severe or chronic gastrointestinal conditions

Primary Use Case

Fat loss, aggressive and sustained, is what Retatrutide was built for.

Phase 2 clinical trials recorded average weight reductions of 17 to 24% of total body weight across 48 weeks, outperforming every other compound in its class at the time those results were published. Phase 3 data has continued to validate and extend those findings. In the TRIUMPH-1 trial, participants receiving Retatrutide achieved mean weight reductions of approximately 22.8% over 48 weeks, with a significant proportion losing more than 25% of their total body weight, an outcome that had not been consistently achieved with any prior approved therapy in this class. Importantly, Phase 3 results confirmed that the weight loss trajectory had not plateaued at 48 weeks in a meaningful portion of participants, suggesting continued fat loss potential with extended use.

The tri-agonist mechanism makes it particularly well-suited for individuals carrying significant metabolic resistance who have failed to respond adequately to prior interventions.

Beyond fat loss, secondary benefits include meaningfully improved insulin sensitivity, favorable shifts in cardiovascular markers, measurable reductions in visceral adipose tissue, and promising data on liver fat improvement (NAFLD/NASH). Phase 3 data also demonstrated statistically significant reductions in waist circumference, triglycerides, and HbA1c across the trial population, reinforcing the compound's metabolic breadth beyond simple weight reduction.

These outcomes have been consistently discussed across UK, German, French, and broader EU metabolic health communities as access to research-grade Retatrutide across Europe has expanded.

Dosing Protocol

Given its potency, Retatrutide demands a conservative titration schedule. Accelerating the ramp-up is the fastest way to turn manageable side effects into a miserable experience.

Route: Subcutaneous injection Injection site: Abdomen, thigh, or upper arm. Rotate sites each injection. Frequency: Once weekly Reconstitution: Combine lyophilized powder with bacteriostatic water prior to use

Suggested titration:

Week 1: 1mg once weekly Weeks 2 to 4: 1mg Monday + 1mg Thursday Weeks 5 to 8: 2mg Monday + 2mg Thursday Weeks 9 to 12: 4mg Monday + 4mg Thursday

Do not advance to the next dose tier until gastrointestinal side effects are fully under control at your current level. The majority of users land at an optimal maintenance dose between 6mg and 8mg weekly.

What To Expect: Timeline

Weeks 1 to 2: Appetite begins pulling back. Nausea is possible, especially in the days following a dose increase. Energy may temporarily dip as caloric intake starts to fall.

Weeks 3 to 6: Appetite suppression becomes reliable and consistent. The scale starts moving. GI side effects typically settle as the body acclimates to the current dose tier.

Weeks 6 to 12: Fat loss becomes visually apparent, especially around the midsection. Metabolic markers and energy levels often improve in tandem. The majority of users notice a dramatic reduction in food noise, the constant intrusive mental chatter about eating.

Weeks 12 to 24: Meaningful body composition changes are the norm at this stage. Trial data supports average losses of 10 to 17% of body weight within this window when dosing, diet, and activity remain consistent.

Weeks 24 to 48: Fat loss continues progressing toward its ceiling. Phase 3 data confirms this is where the most dramatic separation from earlier GLP-1 class compounds becomes apparent. Users who maintained consistent dosing, adequate protein intake, and resistance training through this window achieved the most significant body composition outcomes in the TRIUMPH-1 trial. Peak efficacy appeared at the 48-week mark, with a notable subset continuing to lose weight beyond that point.

Weeks 48 and beyond: Phase 3 data suggests that a meaningful proportion of participants had not reached their weight loss ceiling at 48 weeks, which distinguishes Retatrutide from Semaglutide and Tirzepatide where plateaus tend to emerge earlier. At this stage, preserving lean mass moves to the top of the priority list. Consistent resistance training and hitting protein targets daily are non-negotiable.

Stack Compatibility

Pairs well with:

• BPC-157 for gut lining support, especially valuable during titration when GI stress is at its highest
• Tesamorelin to layer targeted visceral fat reduction on top of systemic fat loss
• MK-677 (Ibutamoren) at conservative doses to maintain GH levels and protect lean mass during aggressive caloric restriction
• A structured resistance training program and a high-protein diet to offset any lean mass loss

Use with caution:

• Insulin and insulin secretagogues. Additive glucose-lowering effects create real hypoglycemia risk. Monitor closely.
• Other appetite-suppressing compounds. Stacking these can drive caloric intake to unsustainably low levels.

Avoid:

• Running any other GLP-1, GIP, or glucagon agonist simultaneously (Semaglutide, Tirzepatide, etc.)
• Pairing with aggressive cutting stacks in the absence of regular bloodwork and qualified medical oversight

Side Effects

The side effect profile mirrors the broader GLP-1 class but is amplified by the glucagon component. Nearly all adverse effects are dose-dependent and manageable with a disciplined titration approach.

Nausea: the most frequently reported effect, peaking around dose increases. Typically resolves within 1 to 2 weeks at each tier. Vomiting: less common, but a real possibility if dose escalation is too aggressive. **Diarrhea or constipation:**altered GI motility is common in the early weeks. Hydration and dietary fiber are your first line of defense. Appetite suppression beyond intent: under-eating becomes a genuine risk. If you are not actively tracking protein, muscle loss follows. Fatigue: shows up early in titration as calories drop. Resolves in most users as intake stabilizes. Injection site reactions: transient redness or mild irritation at the injection site. Elevated resting heart rate: a known consequence of glucagon receptor activity. Anyone with a cardiac history should monitor this closely.

Safety and Regulatory Context

Retatrutide does not hold FDA approval and carries no EMA or MHRA approval for clinical use in the EU or UK. It is available strictly as a research peptide and should be treated accordingly. Regulations vary by country across Europe, so always verify the legal status in your specific jurisdiction before purchasing.

That said, the Phase 2 and Phase 3 trial data behind Retatrutide is among the most robust of any compound in this class. This is not a speculative research chemical. It is a compound with documented, peer-reviewed clinical outcomes that simply has not yet completed the full regulatory approval process.

Reconstitution

Retatrutide typically comes in a 10mg vial.

10mg vial, add 2mL BAC water: 10mg divided by 2mL = 5mg per mL

Your working concentration is 5mg per mL.

To hit common doses:

0.5mg dose = 0.1mL = 10 units on a 100-unit syringe 1mg dose = 0.2mL = 20 units on a 100-unit syringe 2mg dose = 0.4mL = 40 units on a 100-unit syringe 4mg dose = 0.8mL = 80 units on a 100-unit syringe

Reconstitute by injecting BAC water slowly down the side of the vial. Do not inject directly onto the powder. Do not shake. Swirl gently until fully dissolved.

Storage after reconstitution: refrigerate at 2 to 8°C. Do not freeze. Use within 28 days of reconstitution. Keep away from direct light at all stages.

Practical Takeaways

• Retatrutide is the most potent fat loss compound in the GLP-1 class by a significant margin
• Phase 3 TRIUMPH-1 data confirmed average weight reductions of approximately 22.8% at 48 weeks, with a significant subset exceeding 25% total body weight loss
• Phase 3 also demonstrated meaningful reductions in waist circumference, triglycerides, and HbA1c, confirming metabolic benefits extend well beyond fat loss alone
• The glucagon receptor component is what separates it from Semaglutide and Tirzepatide. It does not just cut intake, it actively drives energy output
• Titration is not optional. Rushing the ramp-up is the single most common mistake users make
• Muscle preservation becomes critical after week 12. Protein targets and resistance training are non-negotiable at this stage
• Unlike earlier compounds in the class, Phase 3 data suggests the weight loss trajectory had not plateaued for many participants at 48 weeks, making this a genuine long-game compound in a way Semaglutide and Tirzepatide are not
• In the EU and UK, Retatrutide is available as a research peptide from a growing number of vendors. Source only from vendors providing verified third-party COAs
• Peak results in clinical trials appeared at the 48-week mark. Treat this as a long-game compound and plan your protocol accordingly.

Community

If you have run Retatrutide in the UK or Europe, your data is particularly valuable here given differences in vendor access, peptide quality, and sourcing options across the continent:

• What was your starting dose and how did you titrate?
• How quickly did appetite suppression kick in and how significant was it?
• Did you experience the food noise reduction effect and how dramatic was it?
• What was your total weight loss and over what timeframe?
• Did you stack anything alongside it and did that change your results?
• How did it compare to Semaglutide or Tirzepatide if you have run either?

KLOW is one of those blends people treat like a general "recovery peptide," when in reality it is four distinct compounds hitting four completely different repair mechanisms simultaneously.

Each compound in KLOW is doing something the others cannot. TB-500 mobilizes cells and rebuilds structure through actin regulation. BPC-157 drives angiogenesis and growth factor signaling to push tissue back together. KPV shuts down the inflammatory cascade at the NF-kB level before it can stall the healing process. GHK-Cu rebuilds the extracellular matrix and resets gene expression toward regenerative patterns.

One compound alone gives you one entry point into the repair cascade. KLOW gives you four.

Let's go through it.

Interest in KLOW across the UK, Europe, and the broader EU peptide community has grown considerably, particularly among users dealing with chronic injuries, connective tissue damage, and post-surgical recovery. But most people running it are still treating it like a single-compound protocol. Understanding what each component actually does changes how you use it entirely.

What KLOW Actually Is

KLOW is an 80mg multi-peptide blend in a single lyophilized vial containing:

TB-500 (synthetic thymosin beta-4): 10mg BPC-157: 10mg KPV (lysine-proline-valine): 10mg GHK-Cu (glycyl-L-histidyl-L-lysine-copper): 50mg

None of these are exogenous growth hormones. None override your endocrine system. These are signaling peptidesthat work by activating repair pathways already present in your body but underperforming due to injury, age, or chronic inflammation.

What Each Compound Does

KPV (Lysine-Proline-Valine)

KPV is a tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Three amino acids: lysine, proline, valine. Despite its size, it carries the full anti-inflammatory potency of its parent hormone without the melanocortin receptor activation that produces tanning or broader hormonal effects.

Its mechanism: KPV enters intestinal epithelial and immune cells via the PepT1 transporter and directly inhibits NF-kB and MAPK inflammatory signaling pathways. NF-kB is the master transcription factor governing production of TNF-alpha, IL-6, IL-1beta, and other pro-inflammatory cytokines. Blocking NF-kB upstream means the entire downstream cytokine cascade gets quieted simultaneously.

Research published in Gastroenterology demonstrated that nanomolar concentrations of KPV inhibited NF-kB and MAPK activation and reduced pro-inflammatory cytokine secretion in human intestinal epithelial and immune cells. Oral KPV also reduced colitis severity in two separate murine models. PepT1 expression is upregulated in inflamed tissue, meaning KPV is preferentially absorbed where inflammation is most active.

In the context of KLOW as an injectable blend, KPV provides the inflammatory brake that the other three compounds lack. BPC-157 and TB-500 drive structural repair. GHK-Cu drives matrix remodeling. KPV prevents the chronic inflammatory environment from blocking all of that.

There are no completed human clinical trials evaluating injectable KPV for systemic anti-inflammatory applications.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic peptide derived from the active region of thymosin beta-4, a protein your body naturally produces in platelets, white blood cells, and wound fluid. After injury, thymosin beta-4 is one of the first molecules released at the damage site.

Its primary mechanism: actin regulation. TB-500 sequesters actin monomers, which modulates cytoskeletal dynamics and enables cell migration. When cells cannot migrate efficiently, they cannot reach the injury site. TB-500 resolves that bottleneck.

Beyond cell migration, it promotes angiogenesis (new blood vessel formation), suppresses inflammation, reduces apoptosis, and stimulates keratinocyte and stem cell mobilization. In phase 2 dermal trials, thymosin beta-4 accelerated wound healing in patients with stasis and pressure ulcers. Animal data consistently shows faster reepithelialization, increased collagen deposition, and improved wound contraction across multiple models including diabetic and aged mice.

There are no completed large-scale human clinical trials evaluating TB-500 specifically for musculoskeletal injury in the general population.

BPC-157 (Body Protection Compound)

BPC-157 is a 15-amino acid pentadecapeptide isolated from human gastric juice. It is stable, resistant to enzymatic digestion, and has demonstrated healing activity across a broader range of tissue types than almost any other research peptide studied.

Its mechanism is multifactorial. BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, amplifying the proliferative response of growth hormone at the injury site. It activates the JAK-2/STAT pathway downstream of that receptor and promotes angiogenesis through VEGFR2 upregulation and nitric oxide modulation. It also reduces pro-inflammatory cytokines while supporting vascular recruitment to damaged tissue.

In animal models, BPC-157 has demonstrated consistently positive healing outcomes across tendon rupture, ligament tears, muscle transection, bone fracture, gut mucosal injury, corneal damage, and nerve injury. A 2024 systematic review of 36 studies found structural, biomechanical, and functional improvements in every musculoskeletal model tested.

The one human study: 7 of 12 patients with chronic knee pain reported relief lasting more than 6 months after a single intra-articular BPC-157 injection.

There are no completed randomized controlled human trials for BPC-157. Note: the FDA classified BPC-157 as a Category 2 compound for compounding in 2023. Research use context applies here.

GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper)

GHK-Cu is the highest-dosed compound in KLOW at 50mg, and it is the most extensively studied of the four.

It is a naturally occurring tripeptide-copper complex present in human plasma, saliva, and urine. Plasma levels drop significantly with age, from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. That decline correlates directly with reduced tissue repair capacity.

Its mechanisms: GHK-Cu stimulates collagen I and III synthesis in fibroblasts, increases elastin and glycosaminoglycan production, and regulates matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) simultaneously. This balance is critical. Too much collagen synthesis without adequate MMP activity produces fibrosis and scar tissue. GHK-Cu drives organized matrix remodeling rather than disorganized scar formation.

The copper component acts as a cofactor for lysyl oxidase and lysyl hydroxylase, the enzymes responsible for collagen cross-linking and structural stability. Without adequate copper, newly synthesized collagen is structurally weak and prone to degradation.

In a human topical trial, GHK-Cu improved collagen production in 70% of subjects, outperforming both vitamin C cream and retinoic acid. Gene expression analysis shows GHK-Cu modulates thousands of genes related to tissue repair, antioxidant defense, and inflammation control, with researchers describing the pattern as a partial reversal of age-related gene expression changes.

GHK-Cu is the matrix architecture arm of KLOW. The other three compounds mobilize cells, drive blood vessel growth, and quiet inflammation. GHK-Cu rebuilds the scaffold those cells are supposed to populate.

Why the Blend Makes Sense

These four compounds are not redundant. They address completely separate mechanisms:

KPV: NF-kB and MAPK pathway inhibition, cytokine suppression, anti-inflammatory environment TB-500: cell migration, structural organization through actin, angiogenesis, stem cell mobilization BPC-157: growth factor receptor upregulation, VEGFR2-driven angiogenesis, multi-tissue repair signaling GHK-Cu: collagen and elastin synthesis, MMP/TIMP regulation, matrix remodeling, gene expression reset

Running all four simultaneously means the inflammatory environment gets neutralized (KPV), blood supply to the injury site gets established (BPC-157 and TB-500), cells get mobilized to the repair zone (TB-500), and the structural matrix gets rebuilt correctly (GHK-Cu).

What It Feels Like

Most users notice changes in this order:

Weeks 1 to 2: Reduction in background soreness and joint inflammation. Existing injuries feel less aggravated on a daily basis. Sleep quality often improves slightly.

Weeks 2 to 4: Recovery between training sessions accelerates noticeably. Injuries that had stalled start progressing again. Connective tissue stiffness decreases.

Weeks 4 to 8: Structural changes in previously injured tissue become apparent. Tendons and ligaments that were chronically problematic begin feeling more resilient under load. Skin quality and density improve noticeably for those tracking it.

This is not a pain masking effect. The compounds are not blocking pain signals. The underlying tissue is actually repairing. That distinction matters significantly for how you train and load the tissue during a cycle.

Dosing and Reconstitution

Research use only. Not FDA-approved.

KLOW comes as 80mg lyophilized powder. Reconstitute with 3.0mL bacteriostatic water, giving a total concentration of approximately 26.7mg/mL.

Component concentrations after reconstitution: TB-500, BPC-157, KPV: approximately 3.33mg/mL each GHK-Cu: approximately 16.7mg/mL

On a U-100 insulin syringe: 1 unit equals 0.01mL, delivering approximately 267mcg total peptide.

Titration schedule:

Weeks 1 to 2: 7.5 units (0.075mL) once daily TB-500: 250mcg, BPC-157: 250mcg, KPV: 250mcg, GHK-Cu: 1.25mg

Weeks 3 to 4: 15 units (0.15mL) once daily TB-500: 500mcg, BPC-157: 500mcg, KPV: 500mcg, GHK-Cu: 2.5mg

Weeks 5 to 8: 22.5 units (0.225mL) once daily TB-500: 750mcg, BPC-157: 750mcg, KPV: 750mcg, GHK-Cu: 3.75mg

Weeks 9 to 12 (maintenance): 15 units (0.15mL) once daily

Injection: subcutaneous, once daily. Site rotation recommended.

Storage: lyophilized at -20°C. After reconstitution, refrigerate at 2 to 8°C and use within 30 days. Avoid freeze-thaw cycles.

Side Effects and Safety

The individual safety profiles of all four compounds are favorable based on available preclinical data. No serious adverse events have been reported in the limited human data that exists.

BPC-157: no toxic or lethal dose identified across a wide dose range in animal studies. No gross or histologic toxicity in organs including liver, spleen, lung, kidney, and brain.

TB-500: well tolerated in phase 2 dermal trials. Mild injection site reactions possible.

KPV: no measurable cytotoxicity in epithelial and immune cell lines even at prolonged exposure. No tanning effect. No melanocortin receptor activation at KPV doses.

GHK-Cu: decades of topical and injectable use without significant adverse event reporting. Copper is an essential mineral and the doses in this blend are not approaching toxicity thresholds.

What to watch: injection site irritation, mild transient fatigue in the early weeks as repair processes ramp up, and a potential temporary increase in appetite as anabolic repair signaling increases. These are minor and typically resolve within the first two weeks.

Cancer consideration: GHK-Cu and BPC-157 both interact with growth factor and angiogenic signaling pathways. Anyone with a known active malignancy should not run this blend.

Community

If you have run KLOW in the UK or Europe, your data is especially valuable here given differences in vendor quality, peptide purity standards, and sourcing options across the continent:

• What injury or condition were you targeting?
• How long before you noticed a measurable change in the problem area?
• Did you follow the titration protocol or move straight to the full dose?
• Which component do you believe drove the most noticeable improvement?

For those who keep commenting asking about this, I wanted to do a full breakdown for you. I am going to cover how to reconstitute and fill your bottles correctly, the actual human study doses, the IU to mcg conversion, the vial math, and two practical protocol options that make sense given the constraints of working with research-grade oxytocin.

What the Research Found

Autism (children, crossover): 24 IU/day for 5 weeks. Improved caregiver-rated social responsiveness. Adverse events: thirst, urination, constipation.

Autism (youth, single dose): 18 IU or 24 IU vs placebo. Improved accuracy on emotion recognition tasks compared to placebo.

Autism (2021 NEJM): 290 subjects, 24 weeks. No significant improvement in social or cognitive outcomes. The most rigorous trial in the literature and the one that reset expectations for the field.

Autism (dose-response, adults): 8 IU outperformed 24 IU on overt emotion salience. Direct evidence that more is not better.

Borderline personality disorder (women): Single 24 IU dose 45 minutes before testing. Improved affective empathy and approach motivation in that session.

Clinical high risk for psychosis (men): Single 40 IU dose. Increased heart rate variability in the high-risk group, suggesting improved autonomic regulation. No effect in healthy controls.

Obesity (2024 RCT): 24 IU four times daily for 8 weeks. No reduction in body weight or body composition. Slight reduction in calories consumed at a test meal only.

What the Research Actually Used

Most human nasal oxytocin studies converge on 24 IU per session:

• 3 sprays per nostril = 6 sprays total
• Each spray = 4 IU at 0.10mL
• Total = 24 IU per session

This is the Syntocinon setup. 40 IU/mL concentration, 4 IU per puff, 3 puffs per nostril.

IU to mcg

For oxytocin, 1 IU = approximately 1.67 mcg of pure peptide:

• 4 IU per spray = approximately 6.7 mcg
• 24 IU session dose = approximately 40 mcg
• 40 IU session dose = approximately 67 mcg

The classic human study dose is only 40 micrograms. Not milligrams. This matters enormously when you start doing vial math.

Vial Math

The human study dose is 40 mcg per session. To hit that exactly you would need 12.5mL for a 5mg vial and 25mL for a 10mg vial. Neither divides cleanly into 10mL bottles. The practical solution is to target 500 mcg/mL, which fills 10mL bottles perfectly and brings your dose per spray to 50 mcg. Close enough to the 40 mcg study dose to be meaningful and well within a safe starting range.

5mg vial

5,000 mcg / 500 mcg/mL = 10mL total volume needed

Concentration: 500 mcg/mL = 50 mcg per spray, 100 doses per bottle

10mg vial

10,000 mcg / 500 mcg/mL = 20mL total volume needed

Concentration: 500 mcg/mL across two 10mL bottles = 50 mcg per spray, 200 doses total

How to Reconstitute and Fill Your Bottles

5mg vial — one 10mL bottle

Step 1: Draw 2mL of BAC water and inject slowly into the 5mg vial. Swirl gently, do not shake.

Step 2: Add 8mL of BAC water or sterile saline into your 10mL nasal bottle first. Then draw the entire 2mL from the reconstituted vial and inject it into the bottle.

Your bottle is now 10mL at 500 mcg/mL. Each 0.10mL spray = 50 mcg. 100 doses per bottle.

10mg vial — two 10mL bottles

Step 1: Draw 2mL of BAC water and inject slowly into the 10mg vial. Swirl gently, do not shake.

Step 2: Add 9mL of BAC water or sterile saline into each of your two 10mL nasal bottles first. Then draw 1mL from the reconstituted vial and inject into bottle one. Draw the remaining 1mL and inject into bottle two.

Each bottle is now 10mL at 500 mcg/mL. Each 0.10mL spray = 50 mcg. 100 doses per bottle, 200 doses total.

Use BAC water as your diluent. Stable refrigerated for 4-6 weeks.

Protocol Options

You cannot replicate the exact Syntocinon multi-spray protocol at this concentration without diluting into approximately 150mL across 15 separate bottles. That is not a realistic home setup. These are your two practical options:

Option A: 1 spray total, alternating nostrils each session

50 mcg per session. Closest to the single-dose human study range. This is where everyone starts. Give it several sessions before drawing any conclusions.

Option B: 1 spray per nostril, 2 sprays total

50 mcg x 2 = 100 mcg per session. Above the classic study dose but maintains bilateral delivery. Move here only after you have assessed Option A comfortably.

Bottom Line

• Human studies use 24 IU = approximately 40 mcg per session
• 5mg vial: reconstitute with 2mL BAC water, transfer all 2mL into one 10mL bottle pre-filled with 8mL diluent = 1 bottle, 100 doses
• 10mg vial: reconstitute with 2mL BAC water, transfer 1mL into each of two 10mL bottles each pre-filled with 9mL diluent = 2 bottles, 200 doses
• Each bottle = 500 mcg/mL, each spray = 50 mcg
• Start with Option B: 1 spray alternating nostrils = 50 mcg per session
• Option A: 1 spray per nostril = 100 mcg per session
• Do not chase higher doses, the dose-response curve works against you

Hope this helps! Comment below if you have any questions or if this helped you.

Educational only, not medical advice. 

The number one thing people get wrong about GHK-Cu is assuming it's a skincare ingredient.

It's not. It's a copper-binding tripeptide, glycine-histidine-lysine, that was first isolated from human plasma and has since been shown to orchestrate tissue repair, collagen synthesis, and cellular remodeling at a depth no topical cream can reach. When people apply a GHK-Cu serum to their face and expect meaningful results, they're using a systemic regenerative signal as a moisturizer.

That's the misunderstanding we're addressing today.

Interest in GHK-Cu across the UK, Europe, and the broader EU peptide community has grown steadily, particularly among users focused on skin remodeling, acne scarring, and hair loss protocols. But the topical-versus-injectable confusion is holding most people back from results the compound is fully capable of producing.

What It Actually Does

Collagen synthesis: stimulates fibroblasts to produce Types I, III and IV collagen, the structural proteins responsible for skin firmness and elasticity. Scar remodeling: downregulates TGF-beta 1, the primary driver of scar tissue formation, while promoting controlled, organized healing. PIH and acne lesion resolution: accelerates cellular turnover at damaged skin sites, fading post-inflammatory hyperpigmentation faster than baseline recovery allows. Hair follicle stimulation: increases follicle size and activates regrowth signaling pathways. **Antioxidant upregulation:**activates superoxide dismutase and reduces oxidative stress throughout dermal tissue.

One sentence summary: GHK-Cu restores the repair signaling in your skin back to how it functioned when you were younger.

What It Will and Will Not Do

The mechanism is fibroblast activation. Your fibroblasts produce collagen. GHK-Cu amplifies their output.

Results depend on what you give those fibroblasts to work with. Protein, vitamin C, zinc. If your nutrition is poor, GHK-Cu is pushing against a locked door.

It will: Gradually improve skin density and texture across a full protocol run. Reduce fine lines by thickening the dermal matrix from below rather than filling temporarily. Accelerate acne lesion healing and fade PIH faster than any topical-only routine. Reduce scarring depth over multiple months of consistent use.

It will not: Correct subcutaneous fat distribution. Replace targeted treatment for active cystic acne. Produce visible results within two weeks. Perform optimally from topical application alone.

Realistic Timeline

This is where most posts mislead you. GHK-Cu works through collagen remodeling. That is a slow, structural process. Here is what actually happens and when.

Weeks 1 to 2: Nothing visible. Injection site warmth and brief redness from copper interacting with local tissue. Normal, resolves within an hour. If you are acne prone, you may notice a mild purge beginning here as cellular turnover accelerates. Skin may feel slightly more hydrated if running topical alongside injectable.

Weeks 3 to 6: Subtle texture improvement. Skin starts feeling smoother before it looks different in the mirror. Active acne lesions begin resolving faster than your normal baseline. PIH starts fading earlier than you are accustomed to. These are genuine changes but they are not dramatic yet. This is the phase where most people incorrectly conclude the compound is not working and abandon the protocol.

Weeks 7 to 12: This is where structural change becomes visible. Skin density increases in a way that is difficult to describe until you experience it firsthand. Fine lines soften. Rolling and boxcar acne scars begin filling from the dermal layer upward. Skin reflects light differently. People around you notice something looks different without being able to identify what changed.

Weeks 12 to 16 and beyond: The compounding effect. Users who complete a full 16 week run report the most significant changes in scar depth, skin thickness, and overall skin quality. Those running hair protocols see meaningful follicular changes in this window, reduced shedding first, then new vellus growth at the hairline. This is not a compound where you run 4 weeks and take photos. The best results come from patience and consistency.

Dosing

Standard: 1mg daily for skin remodeling, anti-aging, and acne scarring.

Advanced: 2 to 3mg daily for aggressive scarring protocols or hair loss focus.

Injectable vs topical: Topical reaches the epidermis. Injectable reaches the dermis where fibroblasts actually live. These are not competing approaches. They are two layers of the same protocol. Run both if you can. If you can only choose one, injectable wins by a significant margin for anyone targeting real structural change.

Site specific injection: Community consensus points to injecting near the target tissue. Lateral face or jaw for facial remodeling. Scalp SubQ for hair. Abdomen for systemic effects.

Cycling: 8 to 16 weeks on, 4 to 8 weeks off. GHK-Cu does not downregulate its receptors at standard doses. Longer runs produce better outcomes because collagen remodeling is structural and slow.

Side Effects

What you will actually encounter:

Injection site redness and warmth for 30 to 60 minutes after dosing. Normal copper-tissue interaction, not a cause for concern.

Metallic taste shortly after injection. Uncommon, harmless, disappears for most users after the first week.

Skin purging in weeks 1 to 4 if you are acne prone. Accelerated cellular turnover brings congestion to the surface faster. It looks like a breakout. It is the mechanism working. Push through it.

What is not on the list: No hormonal disruption. No effect on testosterone, estrogen, or the HPG axis. Women can run this without any concern about hormonal interference. No appetite or sleep changes. No liver or kidney stress at research doses. No hormone bloodwork required. No rebound after stopping.

This is one of the cleanest side effect profiles available in the peptide space. It is a key reason GHK-Cu has gained traction in UK and EU wellness and aesthetic medicine circles where tolerability and safety data carry significant weight.

Reconstitution

GHK-Cu comes in 50mg and 100mg vials for injectable use and as a pre-formulated topical solution requiring no preparation.

50mg vial, add 3mL BAC water: 50mg divided by 3mL = 16.7mg per mL 1mg dose = 0.06mL = 6 units on a 100-unit syringe 2mg dose = 0.12mL = 12 units

100mg vial, add 3mL BAC water: 100mg divided by 3mL = 33.3mg per mL 1mg dose = 0.03mL = 3 units on a 100-unit syringe 2mg dose = 0.06mL = 6 units

Topical solution: Apply directly to target areas once or twice daily. No preparation required. Use on the face if injection site discomfort is a barrier. It complements injectable. It does not replace it.

To Sum It Up

Injectable reaches fibroblasts. Topical does not reliably. Run both if possible, injectable if you have to choose.

1mg daily is the working dose. Start at 0.5mg and step up after two to three weeks.

The purging phase is real and temporary. Weeks 1 to 4 may look worse before they look better. This is normal and expected.

For acne scarring and PIH this remains one of the most underutilized tools available. Results in this area are consistent and well documented across the community.

Minimum 12 weeks to see real structural change. 16 weeks is where the most significant results appear. Do not evaluate this compound on a short run.

No hormones affected. No PCT. No bloodwork anxiety. One of the safest additions to any protocol regardless of what else you are running.

In the EU and UK, GHK-Cu is available as a research peptide from a growing number of vendors. Quality varies considerably across European suppliers, which makes sourcing from verified, COA-backed vendors especially important for a compound where purity directly determines results.

Comments

If you have run GHK-Cu in the UK or Europe, your data is particularly useful here given differences in vendor quality, peptide availability, and sourcing options across the continent:

• When did you first notice a visible skin change and what exactly changed?
• Did you experience the purging phase in weeks 1 to 4, how severe and how long did it last?
• Injectable, topical, or both, and did you notice a meaningful difference between the two approaches?
• What dose did you settle on and did you go site specific with your injections?
• Running it for acne or PIH, what was your actual timeline and outcome?

Reconstitution questions come up constantly in the comments and I keep seeing people guessing at the numbers. So here's a follow up to the DIY nasal spray guide with the exact math for every compound, every vial size — how much water goes in the vial, how much goes in the bottle, and what dose you're getting per spray. No more guessing.

A lot of people mess up peptide math because they’re trying to calculate mg per vial, total liquid volume, mcg per spray, or units on an insulin syringe all at once.

So I made a simple calculator for it.

You enter:

mg per vial
how much liquid you’re adding
target dose
spray bottle size / sprays per bottle
or syringe units

And it does the math for you. Just click the Intranasal tab.

Here’s the calculator: DIY Nasal Spray Calculator

The Formula

Vial mode — how much liquid to add:

mL to add = (Mass in vial [mg] × 1000) ÷ Desired dose [mcg] × Volume per spray [mL]

What Water Should You Use?

Before anything else, you need to pick your diluent. This is the liquid you use to dissolve the peptide powder and fill your spray bottle. There are four main options and each has its tradeoffs.

Diluent Options

Sterile Water — no preservative, 5–7 days refrigerated. Fine for short runs.

Saline (0.9% sodium chloride) — more comfortable in the nose, no preservative. Shelf life is generally quoted at 14–21 days. I personally have used saline for up to 31 days with no issues — just my experience before too many of you start asking. Solid option for most peps since you'll go through it quickly anyway.

BAC Water — 0.9% benzyl alcohol preservative, 28–30 days refrigerated. Most common choice. Some find it mildly irritating in the nose over time.

BAC Water + Saline Mix (recommended if you want more sterility) — best of both worlds. 28–30 day shelf life with better nasal comfort than straight BAC water. Only downside is comfort. To make it:

1. Add your reconstituted peptide solution (2 mL from the vial) to the spray bottle first
2. For the remaining volume, split it 50/50 — half BAC water, half saline. So if you need 3 more mL, add 1.5 mL BAC water + 1.5 mL saline
3. Swirl to mix

Two-Step Protocol

Step 1: Add 2 mL of diluent to the peptide vial. Swirl gently until dissolved — never shake.

Step 2: Draw the 2 mL into a syringe, inject into your nasal spray bottle, then top up with remaining diluent to hit your target volume. Swirl to mix.

Reconstitution Steps

1. Let vial reach room temp
2. Draw 2 mL of diluent into syringe
3. Insert needle, angle so liquid runs slowly down the side of the glass — not directly onto the powder
4. Swirl gently until dissolved — never shake
5. Draw the full solution into syringe, inject into spray bottle
6. Add remaining diluent to spray bottle to hit target volume, swirl to mix
7. Label: compound, date, concentration, diluent
8. Refrigerate immediately at 2–8°C

DIY Nasal Spray Peptides

Semax

Cognitive / BDNF | Full dose per nostril each session

5 mg vial

Low — 100 mcg/nostril (200 mcg total)

• Add 2 mL to vial, transfer to bottle, add 3 mL to bottle
• 5 mL total | 1,000 mcg/mL | 25 doses

Standard — 250 mcg/nostril (500 mcg total)

• Add 2 mL to vial, transfer to bottle, no additional liquid needed
• 2 mL total | 2,500 mcg/mL | 10 doses

High — 500 mcg/nostril (1,000 mcg total)

• Add 1 mL to vial, transfer to bottle, no additional liquid needed
• 1 mL total | 5,000 mcg/mL | 5 doses

10 mg vial

Low — 100 mcg/nostril (200 mcg total)

• Add 2 mL to vial, transfer to bottle, add 8 mL to bottle
• 10 mL total | 1,000 mcg/mL | 50 doses

Standard — 250 mcg/nostril (500 mcg total)

• Add 2 mL to vial, transfer to bottle, add 2 mL to bottle
• 4 mL total | 2,500 mcg/mL | 20 doses

High — 500 mcg/nostril (1,000 mcg total)

• Add 2 mL to vial, transfer to bottle, no additional liquid needed
• 2 mL total | 5,000 mcg/mL | 10 doses

Selank

Anxiolytic / GABAergic | Full dose per nostril each session

5 mg vial

Low — 100 mcg/nostril (200 mcg total)

• Add 2 mL to vial, transfer to bottle, add 3 mL to bottle
• 5 mL total | 1,000 mcg/mL | 25 doses

Standard — 250 mcg/nostril (500 mcg total)

• Add 2 mL to vial, transfer to bottle, no additional liquid needed
• 2 mL total | 2,500 mcg/mL | 10 doses

10 mg vial

Low — 100 mcg/nostril (200 mcg total)

• Add 2 mL to vial, transfer to bottle, add 8 mL to bottle
• 10 mL total | 1,000 mcg/mL | 50 doses

Standard — 250 mcg/nostril (500 mcg total)

• Add 2 mL to vial, transfer to bottle, add 2 mL to bottle
• 4 mL total | 2,500 mcg/mL | 20 doses

High — 500 mcg/nostril (1,000 mcg total)

• Add 2 mL to vial, transfer to bottle, no additional liquid needed
• 2 mL total | 5,000 mcg/mL | 10 doses

Adamax

Cognitive / nootropic blend | 10 mg vial | Dose split between nostrils

Standard — 200 mcg total (100 mcg/nostril)

• Add 2 mL to vial, transfer to bottle, add 3 mL to bottle
• 5 mL total | 2,000 mcg/mL | 25 doses

High — 300 mcg total (150 mcg/nostril)

• Add 2 mL to vial, transfer to bottle, add 1.33 mL to bottle
• 3.33 mL total | 3,000 mcg/mL | 16 doses

Melanotan II

Tanning / libido | 10 mg vial | Dose split between nostrils

Loading — 500 mcg total (250 mcg/nostril) daily until pigmentation achieved

• Add 2 mL to vial, transfer to bottle, add 2 mL to bottle
• 4 mL total | 2,500 mcg/mL | 20 doses

Maintenance — 250 mcg total (125 mcg/nostril) 2–3x per week

• Add 2 mL to vial, transfer to bottle, add 6 mL to bottle
• 8 mL total | 1,250 mcg/mL | 40 doses

PT-141 (Bremelanotide)

Sexual health / MC4R agonist | 10 mg vial | Dose split between nostrils

Low — 500 mcg total (250 mcg/nostril)

• Add 2 mL to vial, transfer to bottle, add 2 mL to bottle
• 4 mL total | 2,500 mcg/mL | 20 doses

Standard — 1,000 mcg total (500 mcg/nostril)

• Add 2 mL to vial, transfer to bottle, no additional liquid needed
• 2 mL total | 5,000 mcg/mL | 10 doses

High — 2,000 mcg total (1,000 mcg/nostril)

• Add 1 mL to vial, transfer to bottle, no additional liquid needed
• 1 mL total | 10,000 mcg/mL | 5 doses

Dihexa

Cognitive / HGF agonist | 10 mg vial | Dose split between nostrils

Low — 50 mcg total (25 mcg/nostril)

• Add 2 mL to vial, transfer to bottle, add 18 mL to bottle
• 20 mL total | 500 mcg/mL | 100 doses

Standard — 100 mcg total (50 mcg/nostril)

• Add 2 mL to vial, transfer to bottle, add 8 mL to bottle
• 10 mL total | 1,000 mcg/mL | 50 doses

High — 200 mcg total (100 mcg/nostril)

• Add 2 mL to vial, transfer to bottle, add 3 mL to bottle
• 5 mL total | 2,000 mcg/mL | 25 doses

BPC-157

Anti-inflammatory / gut healing | 5 mg vial | Dose split between nostrils

Low — 250 mcg total (125 mcg/nostril)

• Add 2 mL to vial, transfer to bottle, no additional liquid needed
• 2 mL total | 2,500 mcg/mL | 10 doses

Standard — 500 mcg total (250 mcg/nostril)

• Add 1 mL to vial, transfer to bottle, no additional liquid needed
• 1 mL total | 5,000 mcg/mL | 5 doses

Intranasal works for systemic and gut effects. SubQ or IM preferred for localized injuries.

Semax + Selank Blend

A lot of people run these two together in a single spray bottle. The math is straightforward — you reconstitute each vial separately with 2 mL, then combine both into one bottle. Each spray then delivers both peptides simultaneously at whatever concentration you mixed to.

Since both Semax and Selank are dosed at full amount per nostril, the blend works the same way — one spray per nostril per dose.

Both 5 mg vials (10 mg total peptide)

Low blend — 100 mcg Semax + 100 mcg Selank per nostril (200 mcg each per dose)

• Reconstitute Semax 5 mg with 2 mL, reconstitute Selank 5 mg with 2 mL
• Combine both into one spray bottle, then add 6 mL to bottle
• 10 mL total | Semax 500 mcg/mL | Selank 500 mcg/mL | 100 sprays = 50 doses

Standard blend — 250 mcg Semax + 250 mcg Selank per nostril (500 mcg each per dose)

• Reconstitute Semax 5 mg with 2 mL, reconstitute Selank 5 mg with 2 mL
• Combine both into one spray bottle — no additional liquid needed
• 4 mL total | Semax 1,250 mcg/mL | Selank 1,250 mcg/mL | 20 sprays = 10 doses

Both 10 mg vials (20 mg total peptide)

Low blend — 100 mcg Semax + 100 mcg Selank per nostril (200 mcg each per dose)

• Reconstitute Semax 10 mg with 2 mL, reconstitute Selank 10 mg with 2 mL
• Combine both into one spray bottle, then add 16 mL to bottle
• 20 mL total | Semax 1,000 mcg/mL | Selank 1,000 mcg/mL | 200 sprays = 100 doses

Standard blend — 250 mcg Semax + 250 mcg Selank per nostril (500 mcg each per dose)

• Reconstitute Semax 10 mg with 2 mL, reconstitute Selank 10 mg with 2 mL
• Combine both into one spray bottle, then add 4 mL to bottle
• 8 mL total | Semax 2,500 mcg/mL | Selank 2,500 mcg/mL | 80 sprays = 40 doses

High blend — 500 mcg Semax + 500 mcg Selank per nostril (1,000 mcg each per dose)

• Reconstitute Semax 10 mg with 2 mL, reconstitute Selank 10 mg with 2 mL
• Combine both into one spray bottle — no additional liquid needed
• 4 mL total | Semax 2,500 mcg/mL | Selank 2,500 mcg/mL | 40 sprays = 20 doses

Storage

Dry powder — refrigerator 6-12 months, freezer 12–24+ months

Reconstituted with BAC water or BAC + saline mix — 28–30 days refrigerated

Reconstituted with saline — 14–21 days refrigerated

Reconstituted with sterile water — 5-7 days refrigerated

Keep away from light and heat. Only freeze non-reconstituted powder.

Hope this helps! Please comment below if you have more questions about the math you are trying to figure out or if you need extra help.

CJC-1295 is one of the most misunderstood peptides in the “GH optimization” space because people lump both versions together like they’re interchangeable.

They’re not.

CJC-1295 with DAC and CJC-1295 without DAC might as well be two completely different drugs.
One is a long-acting GH secretagogue designed to give you a week-long elevation in GH/IGF-1.
The other is literally just a GHRH analog (Mod GRF 1-29) with a half-life so short it might as well evaporate as soon as you pin it.

But online, people throw them around like “CJC 1295 is CJC 1295.”

No. Let's actually break down what's happening here.

Interest in CJC-1295 across the UK, Europe, and the broader EU peptide community has grown considerably over the past few years, particularly among users looking for a cleaner, more physiologic alternative to exogenous HGH. But the confusion between DAC and no-DAC versions is widespread, and it's costing people results.

Misconception

“CJC-1295 boosts growth hormone.”

Technically true, but not exactly.

CJC isn’t just “boosting GH.”
It’s manipulating:

• amplitude of GH pulses
• frequency of GH pulses
• IGF-1 output
• sleep-associated GH release
• connective tissue remodeling
• fat mobilization
• recovery signaling

The way it changes these depends entirely on DAC vs no-DAC.

CJC-1295 (No-DAC) — What It Actually Is

CJC no-DAC is Mod GRF 1-29.
It’s the short-acting version with a half-life so short it practically evaporates.

Half-life: ~30 minutes
Duration: ~2 hours
Pinnable: multiple times per day

Its purpose is simple:

You amplify your body’s natural GH pulses.

It synergizes extremely well with:

• Ipamorelin
• GHRP-2
• GHRP-6

This is the combo that actually mimics physiologic GH output — not this “24/7 GH exposure” nonsense anti-aging clinics love.

CJC-1295 (With DAC) — The Long-Acting Version

CJC-1295 with DAC behaves like a totally different drug.

Half-life: 5–8 days
Duration: 1–2 weeks
Pinnable: once or twice weekly

DAC (Drug Affinity Complex) binds the peptide to albumin, making it circulate forever.

Instead of pulses, you get:

a flat, consistent elevation in GH and IGF-1.

This is why clinics push it.
It’s convenient — but convenience doesn’t mean optimal physiology.

Flattening your GH curve isn’t “natural.”
But if your goal is stable IGF-1, DAC gets the job done.

How CJC-1295 Relates to Muscle Building (What Actually Matters)

People talk about CJC like it’s “GH for people who don’t want GH.”
That’s not how this works.

Here’s what it actually does:

1. CJC Increases GH → IGF-1 → Hypertrophy Signaling

IGF-1 matters because it:

• increases muscle protein synthesis
• activates satellite cells
• accelerates connective tissue regeneration
• improves nutrient partitioning
• enhances recovery ability
• supports collagen repair

These pathways are indirectly anabolic.
Not steroids-level anabolic.
But the environment for muscle growth improves.

2. No-DAC = Better Pulses → Better Fat Loss, Sleep, Recovery

Short bursts mimic your body’s natural rhythm, which improves:

• nighttime GH peaks
• fat mobilization
• sleep depth
• training recovery

It won’t build slabs of muscle, but recovery becomes more predictable.

3. DAC = Sustained IGF-1 Elevation → Better Tissue Repair

You don’t get big spikes.
You get a consistent, weak GH/TRT-like elevation.

This can create:

• slightly fuller muscles
• improved tissue repair
• stable recovery signals

It’s more “anti-aging clinic GH-lite” than actual performance enhancement.

Bottom Line for Muscle Building

CJC isn’t building the muscle for you —
it’s improving the internal conditions that help you build muscle.

Where CJC-1295 Is Actually Used Clinically (Worldwide)

CJC-1295 does not hold FDA approval in the US. That doesn't make it worthless. It means the US drug approval process moves slowly and selectively.

Globally, the picture looks different.

CJC-1295 was originally developed in Canada by ConjuChem as a long-acting GHRH analog. Clinical research and therapeutic application have taken place in:

• Canada
• China
• Turkey
• South Korea
• Italy
• Malaysia
• Southeast Asia
• Middle Eastern regions

In the EU and UK specifically, CJC-1295 is available as a research peptide and is used within private regenerative medicine and wellness clinics across Germany, the Netherlands, France, Scandinavia, and the broader European market. It holds no EMA or MHRA approval for clinical use, but its presence in legitimate private practice settings across Europe is well established.

Its primary clinical applications include:

1. Growth Hormone Deficiency (GHD) Originally developed as a long-acting alternative to daily GH injections.
2. HIV-Associated Lipodystrophy GH secretagogues were evaluated for their ability to improve visceral fat distribution, insulin sensitivity, and metabolic markers. CJC was included in these trials.
3. Regenerative and Metabolic Medicine in Private Clinics Globally Commonly applied for fat loss, sleep enhancement, skin quality, muscle repair, and metabolic improvements. Not an approved indication, but legitimate practice in many regions including across Europe.

This isn't a back-alley peptide. It has genuine clinical roots.

1. Growth Hormone Deficiency (GHD)

Developed to replace daily GH injections with a long-acting alternative.

2. HIV-Associated Lipodystrophy

GH secretagogues were tested to improve:

• visceral fat distribution
• insulin sensitivity
• metabolic markers

CJC was part of these trials.

3. Regenerative / metabolic medicine (private clinics globally)

Often used for:

• fat loss
• sleep enhancement
• skin quality
• muscle repair
• metabolic improvements

This isn’t “approved indication,” but it is legitimate practice in many regions.

In other words:
This isn’t a back-alley peptide.
It has real clinical roots.

Mechanism — Why They Feel Different

CJC No-DAC

• short acting
• preserves natural GH pulses
• synergizes with GHRPs
• better for fat loss
• better for sleep and recovery
• lower chance of desensitization

CJC With DAC

• long acting
• sustained IGF-1 elevation
• fuller tissues
• more water retention
• higher chance of desensitization
• less physiologic GH rhythm

Completely different tools for completely different goals.

What You Actually Feel

CJC No-DAC

• deeper sleep
• smoother recovery
• subtle fat loss
• mild fullness
• better nighttime GH pulses

Best with Ipamorelin.

CJC With DAC

• higher IGF-1
• more water retention
• fuller pumps
• better tissue repair
• possible lethargy
• weak GH-like effects

Think: GH-lite, not GH.

Dosing

CJC No-DAC (Mod GRF 1-29)

100 mcg 1–3× daily
Often paired with 100 mcg Ipamorelin

Timing:

• morning fasted
• post-training
• before bed

CJC With DAC

2-2.5mg twice weekly

Side Effects

No-DAC

• flushing
• head pressure
• hunger (if paired with GHRPs)

DAC

• water retention
• numb hands
• lethargy
• elevated fasting glucose
• tingling fingers
• carpal-tunnel-like GH sides

Not dangerous — just predictable.

Risks

• flattened GH pulses (DAC)
• insulin resistance (DAC)
• tolerance with long-term use
• Common mislabeling, particularly with DAC products. This is a known issue across EU and UK research peptide suppliers and a key reason sourcing from vendors with third-party certificates of analysis matters
• unnecessary stacking with MK-677/GH

This stuff is mild compared to anabolic steroids, but it’s not a toy.

Practical Takeaways

• CJC no-DAC and CJC DAC are totally different drugs
• No-DAC = fat loss, recovery, physiologic pulses
• DAC = stable IGF-1, convenience, GH-lite effects
• Neither compares to real GH for actual performance enhancement
• Both improve the environment for muscle growth, not the muscle itself
• Clinics use DAC because it’s easy; bodybuilders use no-DAC because it’s effective

Once you understand the mechanism, the protocols actually make sense.

Community

Curious about four things:

1. Did CJC no-DAC vs DAC actually feel different for you?
2. Fat loss, recovery, sleep — did either one stand out?
3. If you ran no-DAC with Ipamorelin, did the synergy noticeably improve sleep or fat loss?
4. For those who used DAC, did your IGF-1 actually increase on labs — and did that translate to anything real?
5. Anyone here used both peptides and real GH — and how big was the difference?

Post your logs, dosing, timelines, and side effects below.

Melanotan II is one of those peptides everyone jokes about until they actually run it… and suddenly the meme makes sense.
You go outside for 10 minutes, come back looking like you spent a week in Ibiza.
And people still pretend this is “just a tanning peptide.”
It’s not.
It’s literally a melanocortin receptor agonist with systemic side effects some useful, some not, some hilarious.

But you need to understand the underlying biology or you’re going to get blindsided by the real effects.

Interest in Melanotan II across the UK, Europe, and broader EU peptide communities has surged in recent years, particularly among users in countries where tanning culture and sun exposure are central to lifestyle. But most people are running it wrong.

What MT2 is actually doing

Let’s break it down in a way that isn’t bro-science:

Melanotan II is a synthetic analog of α-MSH (alpha-melanocyte stimulating hormone).
That means it’s hitting MC1R the receptor responsible for melanin production but it’s also hitting MC3R, MC4R, and MC5R to varying degrees.

And that’s where the side effects come from.

MC1R → melanin → darker skin
MC3R → appetite modulation
MC4R → libido/erectile function
MC5R → sebaceous glands, sweating, secondary effects

People act surprised when they get random libido spikes or appetite suppression.
It’s not magic.
It’s literally built into the receptor profile.

This is why some guys tan insanely fast genetics.

Why you tan so fast

Most people underestimate how much melanin synthesis MT2 amplifies.

When you pin MT2, you’re basically telling your melanocytes:

“Go. All of you. Right now.”

So even minimal UV exposure like walking outside triggers disproportionately high melanin output.
This is why:

– you tan faster
– your tan gets darker
– you hold color longer
– and you burn significantly less

This isn’t bronzer.
This is literally altering how your melanocytes respond to UV radiation.

For users across the UK and Northern Europe where natural sun exposure is limited, this makes MT2 particularly effective at achieving a deep, lasting tan even from brief tanning bed sessions or the occasional sunny day.

What it feels like

People underestimate the subjective experience:

Day 1–3:
Transient nausea, slight flushing. Classic MT2 response.
If you dose too aggressively out of the gate, you will absolutely feel it.

Week 1:
You start picking up color from incidental sunlight.
You’ll look down at your arms and see that “holy sh*t” moment.

Week 2–3:
The tan becomes noticeable to everyone else.
UV sessions (sun or tanning bed) become absurdly efficient.
Your skin tone gets deeper and more uniform.

Week 4+:
You hit that “Mediterranean for no reason” look.
Color retention goes way up melanin stays elevated even without continuous exposure.

This is the effect that makes MT2 so popular in the UK and across Northern and Central Europe, where achieving and maintaining a deep tan through natural sun alone is simply not realistic for most of the year.

Libido effects

Everyone pretends they don’t want to talk about this, but let’s just be adults.

Melanotan II hits MC4R hard enough that erectile function goes up in many users.
This is the same receptor targeted in pharmaceutical libido drugs being tested right now.

So yes, MT2 increases libido in many people.
No, it’s not “in your head.”
Yes, this is normal.
No, it doesn’t mean something is wrong with you.

Side effects

The commonly reported ones:

– nausea (dose-dependent)
– flushing
– darkening of existing moles/freckles
– increased libido
– appetite suppression

The mole darkening is the one people ignore.
If you have atypical nevi, family history, or any suspicious lesions, don’t run MT2.
This isn’t fearmongering overstimulating melanocytes is not something you want to do if you're already at risk.

Safety

This needs to be stated clearly:

Melanotan II is not FDA-approved, and it holds no EMA or MHRA approval for human use in the EU or UK. There is no long-term human data on chronic usage. Peptide quality between research suppliers varies considerably, particularly across European vendors where regulatory oversight differs by country.

If you’re going to run it, understand what system you’re messing with.

Dosing

Loading Phase Weeks 1–2

• Days 1–3 → 0.25mg daily

• Days 4–7 → 0.5mg daily

• Week 2 → 0.5–1mg daily

(Build base melanin / faster tanning response)

Tanning Phase Weeks 3–6

• 0.5–1mg on tanning days

• Dose 30–60 minutes before UV exposure

• 2–4 tanning sessions per week

(Adjust based on skin type / darkness response)

Maintenance Phase Weeks 7–12

• 0.25–0.5mg 2–3× weekly

• Maintain desired color

• No daily dosing needed

Reconstitution

10 mg vial
Add 2 mL BAC → 5 mg/mL

1 mg = 0.2 mL
0.5 mg = 0.1 mL

Why people actually run MT2

It's not just tanning. It's:

• photoprotection
• cosmetic enhancement
• confidence going into summer
• holiday and vacation prep
• bodybuilding stage prep
• libido benefits
• meaningfully reduced burn risk

It fundamentally changes your relationship with UV exposure. For users in the UK and across Europe where sun is a seasonal luxury, that shift is especially significant.

Community

If you've run MT2 in the UK or Europe, share what your response profile actually looked like. European user data is particularly useful here given the differences in skin types, UV availability, and tanning bed culture across the continent:

– How fast did your tan actually develop?
– Did you get the nausea?
– Did libido spike or stay baseline?
– Did your moles darken?
– Did you respond better to sun or tanning beds?

Drop it below.

Tesamorelin is one of those peptides that gets tossed around in conversations like it's some kind of magic "fat-loss injection," when in reality it's a very specific, highly targeted growth-hormone-releasing analog that does one thing exceptionally well: elevate GH and IGF-1 through a clean, predictable GHRH pathway.

Interest in Tesamorelin across the UK, Europe, and the broader EU peptide community has grown significantly over the past few years, and for good reason. But the problem is people approach it like a shortcut. It isn't. It's a precision tool. And to use it correctly, you need to understand what it actually does, and more importantly, what it doesn't do.

Let's break it down.

Mechanistically -- What Tesamorelin Actually Does

Tesamorelin is a stabilized GHRH analog. Meaning: it closely mimics the exact hormone your hypothalamus uses to signal your pituitary: "Release more growth hormone."

But unlike natural GHRH, which gets broken down faster than your willpower on a cut, Tesamorelin is structurally modified to survive long enough to produce a GH spike in a far more reliable, sustained way.

The key points:

• Increases pulsatile growth hormone secretion. You're amplifying the body's natural pulses, not suppressing them with the constant GH elevation that exogenous HGH produces
• Raises IGF-1 significantly, typically in the same range as 1 to 2 IU of pharmaceutical GH
• Enhances lipolysis and drives visceral fat reduction, which is the part everyone fixates on
• Carries a relatively clean receptor profile with no artificial GH spillover and no off-target activity

If your goal is to support the physiologic pattern of GH rather than override it entirely, Tesamorelin makes more sense than exogenous growth hormone for the majority of people. This holds true whether you're running it in the UK, Germany, the Netherlands, Scandinavia, or anywhere else in Europe where access to quality research peptides has expanded considerably in recent years.

Why It Works So Well for Fat Loss, Specifically Visceral Fat

This is the part most people consistently misunderstand, and it comes up constantly in European and UK peptide communities.

Tesamorelin wasn’t designed as a bodybuilding drug.
It was FDA-approved to reduce excess visceral adipose tissue (VAT) in HIV patients with metabolic disturbances.

And it turns out… the mechanism they were targeting applies to everyone:

GH → increases lipolysis → preferentially mobilizes visceral fat first.

Subcutaneous fat loss still improves, but VAT is the big mover.
If you’ve ever wondered why some guys look like they’re lean on the outside but still have that “GH gut” appearance — that’s visceral fat.

Tesamorelin helps reverse that.

It doesn’t magically chisel you if you’re eating garbage.
But if your diet is dialed in, Tesamorelin gives you a noticeably tighter midsection, improved insulin sensitivity, and better nutrient partitioning.

These outcomes have been consistently reported by users across UK, German, French, and broader Europe fitness communities running it as a standalone research peptide.

What It Feels Like in Real Life

The subjective effects are pretty consistent:

Week 1:
Sleep quality bumps up a bit.
You feel warmer at night.
Some guys report mild water retention, nothing crazy.

Week 2–3:
You notice subtle changes in midsection tightness.
Recovery gets slightly better.
Pumps improve.

Week 4–8:
This is where people start seeing the visceral fat reduction.
Your waist just looks smaller even if scale weight hasn’t changed.
IGF-1 is typically sitting in the upper-normal to supraphysiological range.

No, you’re not suddenly blasting GH like a 1990s bodybuilder.
But the “I just look healthier and tighter” effect is very real.

Dosing

The clinically validated dose:

2 mg subcutaneous once daily

Yes, 2 mg.
Not 500 mcg.
Not 1 mg.
Tesamorelin has been studied extensively — 2 mg is where you get the meaningful bump in IGF-1 and visceral fat reduction.

Some people do run it at 1-1.5mg though if cost is a concern and still are able to get some good results out of it.

Timing:
Most people pin it before bed, but physiologically it doesn’t matter that much because it amplifies your normal GH pulses.
Pre-sleep is just convenient.

Side Effects

The ones you'll actually encounter:

• Edema and water retention
• Mild tingling or numbness
• Transient insulin resistance (rare, but worth knowing)
• Increased appetite driven by IGF-1
• Vivid dreams
• Mild fatigue in the first week

Notice what's absent from that list: No prolactin elevation. No estrogen complications. No thyroid suppression. None of the predictable fallout that comes with exogenous GH overdosing.

Tesamorelin has a surprisingly favorable tolerability profile, which is a large part of why it has become one of the most discussed GHRH analogs across UK and EU peptide research communities in recent years.

Risks and Safety

Here's the honest assessment:

Tesamorelin holds FDA approval but only in its pharmaceutical form (Egrifta). In the EU and UK, it carries no EMA or MHRA approval for clinical use, meaning it is available strictly as a research peptide and should be treated accordingly. Regulations vary by country across Europe, so always verify the legal status in your specific jurisdiction before purchasing.

That said, the mechanism is well-characterized, the half-life is predictable, and the long-term safety data on therapeutic dosing is substantially stronger than most compounds people inject without a second thought.

On the topic of cancer risk, here's the nuance worth understanding: Growth hormone doesn't cause cancer. But elevated IGF-1 can accelerate the proliferation of already-existing cancer cells.

If you have a known malignancy or any suspicious lesion, this is not a compound you should be touching.

Reconstitution

Tesamorelin typically comes in a 10 mg vial. Reconstitute with 2 mL of BAC water. 10 mg divided by 2 mL = 5 mg per mL Your working concentration is 5 mg/mL.

To hit the 2 mg clinical dose: 2 mg divided by 5 mg/mL = 0.4 mL

On a standard 100-unit insulin syringe: 0.4 mL = 40 units

Practical Takeaways

• Tesamorelin is one of the cleanest GH secretagogues available
• It reliably raises IGF-1 without disrupting natural pulsatility
• It preferentially targets visceral fat, a genuinely rare quality in fat-loss agents
• Sleep quality, recovery, and general sense of wellbeing tend to improve
• The side effect burden is mild relative to exogenous GH
• It has become one of the more widely trusted GHRH analogs within UK and European peptide research communities

It isn't a miracle. It isn't a shortcut. But it is one of the rare compounds where the mechanism and the real-world outcomes actually align.

Community

If you've run Tesamorelin in the UK or Europe, share the real data.

• How long before your waist measurement shifted?
• Did you experience appetite swings from the IGF-1 increase?
• Did you compare the results directly to exogenous HGH?
• Any issues with numbness or water retention?
• Did sleep quality improve or was the effect negligible for you?
• How did you approach dosing, strictly 2 mg or did you experiment?
• Did visceral fat reduction actually show up in your physique?

Good or bad side effects. Not just nausea or water retention.

Could be better sleep, anxiety disappearing, insane hunger, zero appetite, panic attacks, crazy dreams, skin changes, libido spikes, emotional numbness, feeling “off,” etc.

What compound caused it ?

WHAT IS IT?

The Semax / Selank / Dihexa Nasal Spray is a triple-compound nootropic formulation delivering 5mg of each peptide per bottle in a single intranasal solution. It combines the dopaminergic activation and BDNF upregulation of Semax, the anxiolytic and stress-buffering properties of Selank, and the uniquely potent synaptic growth and memory enhancement of Dihexa into one convenient delivery system. The result is a comprehensive cognitive enhancement stack that addresses focus, anxiety, memory formation, and neuroprotection simultaneously through three distinct and complementary neurological mechanisms.

WHO IS IT FOR?

Ideal candidates:

• Individuals seeking a comprehensive, multi-pathway cognitive enhancement protocol in a single convenient format
• Those who want the combined benefits of Semax and Selank alongside the more potent and longer-acting synaptic enhancement of Dihexa
• People experiencing cognitive decline, memory impairment, or age-related reductions in processing speed and learning capacity
• High-performing individuals in cognitively demanding roles who want a foundational nootropic stack without managing multiple separate compounds
• Those recovering from traumatic brain injury, stroke, or neurological events where BDNF, synaptic growth, and neuroprotection are all priorities
• Biohackers and longevity-focused individuals wanting the most comprehensive nootropic peptide coverage available in a single preparation

Not recommended for:

• Pregnancy or breastfeeding
• Individuals with a history of psychosis, schizophrenia, or significant dopaminergic dysregulation without medical supervision
• Those on MAOIs, benzodiazepines, SSRIs, or SNRIs without medical oversight given the overlapping neurotransmitter activity of all three compounds
• Individuals with active seizure disorders
• People sensitive to stimulant-adjacent effects; the dopaminergic activity of Semax within the blend can produce overstimulation in sensitive users
• Those new to nootropic peptides who have not assessed individual compound tolerance separately; the combination amplifies effects and makes isolating the source of any adverse reaction more difficult

PRIMARY USE CASE

The primary use case for this formulation is comprehensive cognitive enhancement through simultaneous activation of three distinct neurological pathways. Rather than targeting a single mechanism, the combination addresses the full cognitive performance stack including focus and drive (Semax), emotional stability and stress resilience (Selank), and deep synaptic remodeling and memory enhancement (Dihexa) in a single administration.

Dihexa, the third and least commonly known compound in this blend, deserves particular attention. It is a small molecule derived from angiotensin IV that has demonstrated the ability to potently upregulate hepatocyte growth factor (HGF) and its receptor c-Met, which together drive synaptogenesis, the formation of new synaptic connections between neurons. In preclinical research, Dihexa was reported to be approximately ten million times more potent than BDNF in driving synaptogenesis, making it one of the most powerful known promoters of new synaptic growth and one of the most compelling compounds for cognitive restoration and enhancement.

Secondary benefits of the combined formulation include neuroprotection across multiple pathways, reduced neuroinflammation, improved mood and emotional regulation, enhanced learning and memory consolidation, stress resilience, and immunomodulation from Selank's tuftsin-derived activity.

MECHANISM OF ACTION

Each compound in the formulation contributes a distinct and complementary neurological mechanism:

Semax: Dopaminergic Activation and BDNF Upregulation Semax stimulates BDNF and NGF expression in the hippocampus and prefrontal cortex while modulating dopaminergic and serotonergic tone. This produces enhanced focus, motivation, working memory, processing speed, and neuroplasticity. It is the activating and drive-enhancing component of the formulation.

Selank: GABAergic Modulation and Anxiolytic Balance Selank modulates GABAergic tone, slows enkephalin degradation, and upregulates BDNF through a pathway partially distinct from Semax. It provides anxiolytic balance to Semax's dopaminergic activation, preventing overstimulation while adding emotional stability, stress resilience, and immunomodulatory support. It is the calming and balancing component of the formulation.

Dihexa: Synaptogenesis and Synaptic Remodeling Dihexa upregulates hepatocyte growth factor (HGF) and activates its receptor c-Met in brain tissue, driving the formation of new dendritic spines and synaptic connections between neurons. This synaptogenic activity operates at a deeper structural level than BDNF-driven neuroplasticity alone, potentially producing lasting improvements in cognitive architecture rather than purely functional enhancements. It is the deep structural and memory-remodeling component of the formulation.

The Combined Effect The three mechanisms are complementary and largely non-redundant. Semax and Selank both upregulate BDNF through overlapping pathways, producing additive neurotrophic support, while Dihexa's HGF and c-Met-driven synaptogenesis adds a structurally distinct layer of synaptic growth on top. The dopaminergic activation of Semax and the GABAergic balancing of Selank work in opposition to each other in a productive way, producing a state of calm, focused alertness that neither compound achieves as cleanly alone.

DOSING PROTOCOL

Each bottle contains 5mg of Semax, 5mg of Selank, and 5mg of Dihexa in a single intranasal solution. Dosing is administered via nasal spray with each spray delivering a fixed volume of the combined solution.

• Route: Intranasal
• Frequency: Once or twice daily
• Timing: Morning dosing is recommended for most users. A second dose in early afternoon is appropriate for extended cognitive demand but evening dosing should be avoided given Semax's dopaminergic activity and potential for sleep disruption.

Standard dosing:

• Starting dose: 1 spray per nostril once daily (approximately 100mcg of each compound per full dose depending on spray volume)
• Moderate dose: 1 to 2 sprays per nostril once daily
• Higher dose: 2 sprays per nostril twice daily for experienced users with established tolerance

Because Dihexa is significantly more potent per microgram than Semax or Selank, start conservatively and assess cognitive and mood response before increasing dose. Dihexa's effects are longer-lasting than the other two compounds and can accumulate with repeated dosing.

Cycle guidance:

• Standard cycle: Not necessary
• Given Dihexa's potency and longer duration of action, some practitioners recommend shorter cycles of 2 weeks on and 2 weeks off for this combination

WHAT TO EXPECT: TIMELINE

Days 1 to 3: Effects from Semax and Selank are typically noticeable within the first one to two doses. Improved mental clarity, reduced anxiety, enhanced focus, and a calm, alert cognitive state are among the earliest reported effects. Dihexa's synaptogenic effects operate on a longer timeline and are not acutely perceptible in the way that neurotransmitter modulation is.

Days 3 to 7: The Semax and Selank components produce consistent cognitive enhancement and emotional stability. Some users begin noticing improvements in memory recall and information retention by the end of the first week as the early synaptogenic effects of Dihexa begin to contribute alongside the neurotrophic effects of the other two compounds.

Weeks 2 to 4: BDNF upregulation from both Semax and Selank produces cumulative neuroplasticity benefits. Dihexa's synaptogenic activity becomes increasingly apparent in enhanced memory consolidation, learning speed, and associative thinking. Many users report that this is where the formulation feels qualitatively different from Semax and Selank alone, with a deeper and more structural quality to the cognitive improvements.

Weeks 4 to 8: Full cumulative benefits of all three compounds are most evident. Memory, learning, focus, emotional regulation, and cognitive resilience are all improved simultaneously. Users engaged in intensive learning or skill acquisition during this window often report the most significant subjective results given the combination of enhanced encoding (Dihexa synaptogenesis) and improved retrieval and processing (Semax and Selank neurotransmitter modulation).

STACK COMPATIBILITY

Pairs well with:

• MOTS-c for foundational mitochondrial and cellular energy support in neurons alongside central cognitive enhancement
• BPC-157 for gut-brain axis support, systemic anti-inflammatory effects, and dopaminergic system support that complements Semax's mechanism
• Lion's Mane mushroom extract for additional NGF support layered on top of the formulation's BDNF activity
• Low-dose Methylene Blue for mitochondrial electron transport chain support in neurons enhancing the energy substrate available for the synaptic remodeling Dihexa drives
• Omega-3 fatty acids (DHA in particular) to support neuronal membrane integrity and synaptic function alongside Dihexa's synaptogenic activity

Use with caution:

• SSRIs, SNRIs, MAOIs, and other serotonin or dopamine modulating medications given Semax's neurotransmitter activity
• Benzodiazepines and GABAergic medications given Selank's GABAergic modulation
• Racetams and other synaptogenic or cholinergic nootropics given Dihexa's potent synaptogenic activity; additive cognitive stimulation can produce overstimulation in sensitive individuals
• Stimulants including high-dose caffeine given Semax's dopaminergic component

Avoid:

• Evening dosing given Semax's potential for sleep disruption
• Exceeding recommended doses given the potency of Dihexa and the limited human safety data available for all three compounds in combination
• Use without an established tolerance to each compound individually for first-time users if possible; starting with the combination without prior individual compound experience makes adverse reaction assessment more difficult

SIDE EFFECTS

The side effect profile reflects the combined activity of all three compounds. Most adverse effects are mild, dose-dependent, and consistent with the individual compound profiles.

• Mild stimulation or restlessness: driven primarily by Semax's dopaminergic activity; managed by dose reduction or avoiding afternoon dosing
• Mild sedation or cognitive softening: occasionally reported, more likely if Selank's GABAergic effects predominate at the individual level; typically resolves with dose adjustment
• Nasal irritation: the most common practical complaint with intranasal administration of any multi-compound solution; rotating nostrils and allowing 30 to 60 seconds between nostrils minimizes this
• Headache: occasionally reported, typically mild and early in the cycle
• Sleep disruption: possible with afternoon or evening dosing due to Semax's dopaminergic activity; morning dosing mitigates this effectively
• Appetite changes: mild changes in either direction reported by some users
• Overstimulation at higher doses: the combined dopaminergic and synaptogenic activity can produce anxiety, mental racing, or heightened arousal in sensitive individuals; dose reduction resolves this
• Brief adjustment period after cessation: some users report a short window of reduced cognitive sharpness or mild mood changes as neurotransmitter systems normalize; typically mild and brief

Given Dihexa's exceptional potency and limited human safety data, the overall uncertainty profile of this combination is higher than for Semax and Selank alone. Caution, conservative dosing, and medical oversight are particularly important with this formulation.

STORAGE AND HANDLING

• Prepared nasal solution: Refrigerate at 2 to 8°C at all times. Do not freeze.
• Keep away from direct light and heat at all stages; all three compounds have some light sensitivity in solution.
• Do not shake the bottle; gently invert once or twice before use if any settling is observed.
• Use clean technique when administering; avoid touching the spray tip to any surface to prevent contamination.
• Do not transfer to a non-sterile container.

Where To Find Trusted Research Suppliers

For vetted suppliers trusted by this community, see our USP Trusted Vendors List

DISCLAIMER

The information in this guide is intended for educational purposes only and does not constitute medical advice.

This is the index. Every compound gets its own write-up. Every write-up links from here.

Most of what gets shared in this space is either incomplete, misapplied, or built on a game of telephone that started with one study abstract and ended up as gospel. Dosing protocols circulate without the pharmacokinetic reasoning behind them. Stacks get recommended without any explanation of why the mechanisms are complementary. That's the problem this library exists to fix.

The goal is straightforward: close the gap between what the research actually says and what's circulating in the community. Each post follows a consistent structure: mechanism first, data second, real-world context third. Compounds appear in more than one category when their mechanism warrants it.

Bookmark this. Share it when someone asks a question that deserves a real answer instead of a confidence-without-evidence reply. Comment below if it helped.

****This will be constantly edited and hyperlinks will be added****

Materials and Supplies

• Bacteriostatic Water - for reconstituting your peps
• Insulin Syringes (Amazon) - for injection
• Alcohol Swabs (Amazon) - cleaning your vials and injection sites
• Travel Ice Pack TSA Approved (Amazon) - keeping you peps cold while traveling
• Nasal Spay Bottles 10ml sterile - for making DIY Nasal spray solutions

Tools & Quick Links

• Peptide Dosage Calculator — plug in your vial size and BAC volume, get exact syringe units instantly
• Peptide Blends Reconstitution - cheat sheet for every peptide blend

🔥 Fat Loss and Metabolic Function

Peptides and compounds with verified or mechanistically plausible roles in energy expenditure, mitochondrial function, insulin sensitivity, or adipose tissue regulation.

Retatrutide: Triple agonist hitting GLP-1, GIP, and glucagon receptors simultaneously. The most effective weight loss compound currently in development, and the glucagon component is what separates it from everything else.

Tirzepatide: Dual GIP and GLP-1 receptor agonist with some of the strongest weight loss data in the library. The GIP component is specifically what separates its effect size from GLP-1 monotherapy.

Semaglutide: GLP-1 receptor agonist with the most robust clinical trial record in this library for weight loss and cardiovascular outcomes. The benchmark every newer multi-agonist is being measured against.

Cagrilintide: Long-acting amylin analog that increases satiety and slows gastric emptying. Primarily relevant as an adjunct to GLP-1 agonists, where the combination data becomes meaningful.

SLU-PP-332: ERR agonist driving mitochondrial biogenesis and fat oxidation. Early research, but the mechanism is legitimate and worth understanding.

BAM-15: Mitochondrial uncoupler that increases energy expenditure without raising body temperature. Not a peptide, but one of the more mechanistically interesting metabolic compounds currently being studied.

MOTS-c: Mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity. Structurally distinct from a conventional peptide because it originates inside the cell.

SS-31 / Elamipretide: Targets cardiolipin on the inner mitochondrial membrane, improving ATP synthesis efficiency and reducing oxidative stress. One of the more mechanistically specific compounds in this category.

NAD+: Central redox cofactor with well-established metabolic biology. Not a peptide, but the science warrants inclusion regardless.

AOD-9604: C-terminal fragment of hGH isolated for fat oxidation without the IGF-1 and insulin resistance baggage of full-length GH. Effects are real but modest, and the marketing runs well ahead of the human data.

Tesamorelin: GHRH analog with actual clinical approval for visceral fat reduction. The human evidence here is more solid than most of what's in this library.

CJC-1295 No DAC: Produces short, physiologic GH pulses through GHRH receptor stimulation. The No DAC distinction matters: kinetics are fundamentally different from the DAC version.

HGH Fragment 176-191: Same isolated sequence as AOD-9604 under a different name. Enhances lipolysis without raising IGF-1, with real but narrow effects.

💪 Lean Muscle and Recovery: GH / IGF-1 Axis

Peptides that stimulate GH release, modulate IGF-1 activity, or promote tissue repair through anabolic signaling pathways.

Tesamorelin: The most robustly human-validated GHRH analog in this library for body composition. Clinical approval gives it a data floor most compounds in this section don't have.

CJC-1295 No DAC: Produces a natural GH pulse pattern and elevates IGF-1. The No DAC kinetics differ from the DAC version in ways that matter for protocol design.

CJC-1295 + Ipamorelin: GHRH and GHRP synergy that amplifies both GH pulse amplitude and frequency. The gold standard peptide stack for GH optimization and the most popular starting point in this community.

MK-677 / Ibutamoren: Oral ghrelin mimetic that sustains elevated GH and IGF-1 around the clock. Not a peptide, but the go-to for people who want GH benefits without injections.

Sermorelin: GHRH analog that stimulates endogenous GH production rather than replacing it. One of the more forgiving entry points into the GH axis.

Ipamorelin: Ghrelin mimetic that triggers selective GH release without the cortisol or prolactin elevation that comes with less selective GHRPs.

Hexarelin: Potent GHRP with strong GH release and additional cardiac receptor activity. More aggressive than Ipamorelin, with a higher side effect threshold to match.

IGF-1 LR3: Long-acting IGF-1 analog with no approved human indication. Performance claims in this community consistently exceed what the clinical literature supports.

PEG-MGF: Pegylated IGF-1 splice variant targeting satellite cell proliferation and localized muscle repair. No human clinical data, and pegylation meaningfully alters the pharmacodynamics vs. native MGF.

Follistatin-344: Myostatin inhibitor with coherent muscle growth biology. The limitation is that human bioactivity of the injectable form remains largely unvalidated.

🩹 Skin, Wound Healing, and Tissue Repair

Peptides with meaningful evidence for collagen remodeling, skin rejuvenation, or accelerated tissue repair.

GHK-Cu: Copper-binding tripeptide that stimulates collagen and elastin synthesis, with a stronger human and animal study base than most topicals. Delivery method affects bioavailability in ways worth understanding.

GLOW: GHK-Cu, BPC-157, and TB-500 in a single blend targeting collagen synthesis, angiogenesis, and tissue remodeling. The write-up covers how the three mechanisms interact and what the evidence supports for each.

KLOW: GLOW plus KPV, adding an NF-kB suppressing anti-inflammatory layer to the same repair stack. The write-up covers what the fourth compound actually changes about the protocol.

Melanotan 2: Multi-receptor melanocortin agonist that accelerates tanning through receptors that also drive libido effects. That's not a side effect: it's the mechanism.

BPC-157: Consistent angiogenesis and fibroblast migration signals in preclinical wound healing data. Human evidence is sparse, which is a real limitation worth knowing before diving into the full write-up.

TB-500 / Thymosin Beta-4: Facilitates keratinocyte and endothelial cell migration to promote wound closure and tissue remodeling. Preclinical support is solid; controlled human data doesn't exist yet.

KPV: Anti-inflammatory tripeptide that suppresses NF-kB and supports epithelial repair. The same mechanism applies to both skin and gut contexts.

LL-37: Enhances epithelial regeneration and repairs the skin barrier while simultaneously managing microbial burden and inflammation. The dual role is structural, not incidental.

SNAP-8: Topical neuromodulating peptide that reduces expression line depth by dampening neurotransmitter-driven muscle activity. The effect is real but more modest than cosmetic marketing implies.

RU-58841: Topical anti-androgen with a legitimate DHT-driven follicle miniaturization mechanism. Never approved, long-term safety uncharacterized, evidence is mostly early studies and community data.

🧠 Cognitive Function and Neuroprotection

Peptides with genuine mechanistic or evidentiary support for enhancing cognition, neuroplasticity, or protecting neural tissue.

Semax: Clinically used in Russia for BDNF upregulation and post-ischemic recovery. The evidence base is regional, not absent, and that distinction matters when evaluating the data.

Selank: Anxiolytic with cognitive support through GABA and serotonin modulation. Shares the same regional evidence structure as Semax and the same caveats.

Adamax: Modified Semax analog targeting BDNF and TrkB signaling with a more selective receptor profile. Novel compound with early but mechanistically coherent data.

Dihexa: Strong synaptogenic signals in rodent models via HGF/c-Met signaling. The mechanism is interesting; zero human trials exist and long-term safety is unknown.

SS-31 / Elamipretide: Mitochondria-targeted neuroprotection through the same cardiolipin mechanism as its metabolic applications. The dual-category listing reflects a genuinely dual mechanism.

VIP: Neuroprotective and anti-inflammatory signaling across circadian regulation and neurovascular function. Relevant across multiple tissue contexts through the same pathway.

🛡️ Immune Modulation and Inflammation Control

Peptides with well-supported roles in immune regulation, anti-inflammatory activity, or immune restoration.

Thymosin Alpha 1: Clinically validated T-cell and NK-cell modulator used therapeutically for immune deficiency and chronic infection. One of the most established compounds in this entire library.

VIP: Anti-inflammatory and immunoregulatory signaling across multiple tissue types through cytokine modulation and immune tolerance promotion.

KPV: Suppresses NF-kB and pro-inflammatory cytokines through a mechanism that covers both gut and skin immune applications simultaneously.

SS-31 / Elamipretide: Reduces mitochondrial ROS and oxidative inflammation through cardiolipin stabilization. The immune relevance follows directly from the mitochondrial mechanism.

LL-37: Regulates cytokine release, neutralizes bacterial toxins, and balances pro- and anti-inflammatory responses simultaneously. The dual role is structural.

⏳ Longevity and Cellular Protection

Peptides and cofactors with meaningful mechanistic or clinical evidence for impacting cellular aging, telomere dynamics, or mitochondrial integrity.

Epitalon: Pineal tetrapeptide with telomerase activation and circadian normalization data from Russian studies. Independent Western replication is limited, and that belongs in the confidence calculation.

SS-31 / Elamipretide: Reduces oxidative damage and improves ATP efficiency through mitochondrial cardiolipin binding, with human trial exposure across multiple indications.

MOTS-c: AMPK activation and metabolic stress-response support with a longevity signal mechanistically tied to mitochondrial energy status.

NAD+: Central redox cofactor for sirtuins and PARPs. The delivery debate is ongoing; the underlying biology is not.

Thymosin Alpha 1: Immune rejuvenation and cytokine balancing with established clinical use. Immune aging is an underrated driver of the broader longevity picture.

FOXO4-DRI: Induces apoptosis in senescent cells by disrupting the FOXO4/p53 complex. The most direct peptide-based approach to senolytics currently in preclinical research.

❤️ Sexual Function and Hormonal Regulation

Peptides with demonstrated or well-supported links to sexual health, libido, or hormonal axis modulation.

PT-141 / Bremelanotide: FDA-approved MC4R/MC3R agonist that drives libido and arousal through the CNS, not through hormonal changes. The centrally mediated mechanism is what separates it from hormone-based interventions.

Oxytocin: Neuropeptide that enhances bonding, trust, and sexual arousal via limbic system activity. Effects are CNS-driven and highly context-dependent.

Melanotan 2: Central MC4R activation for libido and arousal, sharing the same receptor mechanism as PT-141 with the addition of tanning from its broader receptor activity.

Kisspeptin-10: Activates GnRH neurons to drive LH, FSH, and downstream reproductive hormone release. As far upstream as peptide intervention into the hormonal axis currently goes.

How Each Write-Up Is Structured

Every post opens with a beginner-accessible overview: what the compound is, what it does mechanistically, and what the caveats are. From there: study design, pharmacokinetics, mechanism of action, preclinical and clinical outcomes, safety signals, regulatory context, and a community protocol summary for educational purposes.

The goal is the same across every write-up: give you the tools to evaluate the evidence yourself rather than hand you a verdict to memorize.

All content is for educational and research purposes only. Nothing in this library constitutes medical advice.

If you could rewind to day one, what’s the one thing you’d tell yourself?

Think about the one thing nobody told you that you had to figure out the hard way.

Could be dosing, sourcing, reconstitution, expectations, timing, whatever actually moved the needle.

What is it?

WHAT IS IT?

PT-141 / Oxytocin is a dual-compound nasal spray combining two of the most targeted compounds available for sexual desire, arousal, and intimacy enhancement into a single on-demand formulation. PT-141 activates the brain's desire and arousal circuitry through melanocortin receptor activation while oxytocin, often called the bonding hormone, deepens emotional connection, trust, and the relational quality of sexual experience simultaneously.

The combination addresses something no single compound can achieve alone: the full spectrum of sexual experience from neurological desire and physical arousal through to emotional intimacy and connection. Most sexual enhancement compounds target one dimension. This formulation targets all three at once.

WHO IS IT FOR?

Best suited for:

• Men and women who want the full PT-141 arousal and desire profile with the added emotional depth and connection that oxytocin provides
• Couples dealing with desire discrepancy, emotional disconnection, or reduced relational intimacy where both physiological and psychological dimensions need addressing simultaneously
• Individuals who find PT-141 alone produces strong physical arousal but want the emotional and bonding dimension amplified
• Those dealing with stress, emotional guardedness, or anxiety-driven intimacy barriers where oxytocin's trust and bonding effects directly address the root cause
• Women in particular, where the combination of desire restoration (PT-141) and enhanced emotional safety (oxytocin) addresses the two primary neurological drivers of female sexual responsiveness

Not ideal for:

• Individuals with uncontrolled hypertension or recent cardiovascular events given PT-141's transient blood pressure effects
• Those on antihypertensives without medical supervision
• Pregnancy or breastfeeding; oxytocin has uterotonic effects and is contraindicated in pregnancy
• People with active melanoma history or those who reacted poorly to MT-2
• Individuals who want purely physical enhancement without the emotional and relational dimension; the oxytocin component meaningfully shifts the experience toward connection and vulnerability

HOW IT WORKS

The two compounds operate through distinct but deeply complementary neurological pathways that together produce an experience qualitatively different from either alone:

Step 1: MC3 and MC4 receptor activation (PT-141) PT-141 binds melanocortin receptors in the hypothalamus, directly activating the neural circuitry underlying sexual desire and motivation. This triggers dopamine release in the mesolimbic reward pathway, producing proactive sexual drive rather than reactive arousal. The desire feels internally generated, which is the consistently reported qualitative distinction between PT-141 and every other sexual enhancement compound on the market.

Step 2: Dopaminergic reward activation (PT-141) Mesolimbic dopamine release produces anticipatory pleasure, motivation toward sexual activity, and the heightened engagement that users describe as the compound's most distinctive quality. This is the mechanism that makes sex feel wanted rather than simply possible.

Step 3: Oxytocin receptor activation in the brain and periphery Intranasal oxytocin crosses the blood-brain barrier via the olfactory pathway and binds oxytocin receptors in the amygdala, hippocampus, and hypothalamus. In the amygdala specifically, oxytocin reduces fear and threat-detection signaling, directly lowering the emotional guardedness and stress-driven disconnection that is one of the most common barriers to genuine intimacy, particularly in women.

Step 4: Trust, bonding, and social salience enhancement (Oxytocin) Oxytocin increases the perceived trustworthiness and attractiveness of a partner, enhances emotional attunement, and amplifies the subjective sense of connection during physical contact. Touch feels more meaningful. Eye contact feels more intimate. The emotional dimension of the experience is heightened in a way that purely physical arousal compounds do not produce.

Step 5: Peripheral vascular and physical response (PT-141) Downstream from hypothalamic MC4 activation, PT-141 drives neural pro-erectile signaling in men and increased genital blood flow and lubrication in women through central rather than vascular pathways. This peripheral physical response is additive to the emotional and desire effects rather than the primary mechanism, which is what makes this formulation fundamentally different from anything working purely on blood flow.

The combined effect PT-141 generates the neurological drive toward sex. Oxytocin removes the emotional barriers to it and deepens the quality of the connection during it. Together they address desire, arousal, and intimacy simultaneously in a way that mirrors and amplifies the full natural sexual response rather than isolating a single component of it.

DOSING

Standard dosing per administration:

• PT-141: 1 to 2mg intranasally
• Oxytocin: 20 to 40 IU intranasally
• Timing: 45 to 90 minutes before activity
• Frequency: As needed, maximum once per 24 hours
• Administration: One to two sprays per nostril depending on formulation concentration; wait 10 to 15 seconds between nostrils

Confirm the exact concentration of both compounds per spray with your supplier before calculating per-spray dosing. Formulations vary and accurate dosing requires knowing the specific volume per actuation.

First use protocol: Start at the lower end of both compounds on first use. PT-141's nausea risk is dose-dependent and oxytocin's emotional effects can feel unfamiliar or intense for first-time users, particularly those with significant stress or emotional guardedness in their baseline. Starting conservative allows both compounds to be assessed individually before moving to higher doses.

Common mistakes:

• Treating this as a purely physical enhancement tool; the oxytocin component shifts the experience meaningfully toward emotional openness and vulnerability, which requires the right context to be appreciated rather than felt as disorienting
• Dosing in a rushed, stressed, or distracted context; this combination is particularly sensitive to set and setting given oxytocin's social salience amplification
• Redosing within the same occasion; onset is slower than expected for first-time users and additional dosing increases side effect risk without improving the experience
• Heavy alcohol or large meals before dosing; both blunt absorption and worsen PT-141-related nausea

WHAT TO EXPECT

15 to 30 minutes Facial flushing and mild warmth signal PT-141 absorption. Oxytocin begins crossing into brain tissue via the olfactory pathway. Some users notice a subtle shift in social and emotional warmth toward their partner during this window, a gentle reduction in emotional guardedness that arrives before the more pronounced physical effects.

30 to 60 minutes Sexual desire begins building from the PT-141 dopaminergic component. Simultaneously, oxytocin's amygdala effects reduce anxiety and emotional defensiveness. Touch becomes more meaningful. Emotional attunement to a partner increases noticeably. This combination of rising physical desire alongside deepening emotional openness is the defining characteristic of this formulation versus PT-141 alone.

1 to 4 hours Peak effect window for both compounds. Physical arousal, desire, and emotional connection are all simultaneously active. Men report spontaneous arousal and strong erectile readiness alongside heightened emotional engagement. Women report enhanced sensitivity, lubrication, and a sense of emotional safety and openness that makes physical intimacy feel more natural and less effortful. Both partners typically report that sex feels more present, connected, and mutually engaged than baseline.

4 to 12 hours Gradual taper. The oxytocin component contributes to a notable post-experience warmth and relational closeness that persists well beyond the active window. Many couples report this as one of the most valuable aspects of the combination, a sustained improvement in relational warmth and communication quality in the hours and sometimes day following use.

STACKING

PDE5 inhibitors (Viagra, Cialis, Tadalafil) Adds peripheral vascular mechanics to PT-141's central neural pro-erectile signaling. Particularly valuable for men where vascular erectile dysfunction coexists with desire issues. Start both at lower doses when combining.

DSIP Sleep and HPA axis optimization builds the hormonal and neurological baseline that both PT-141 and oxytocin depend on for maximum response. Chronically poor sleep is one of the most common suppressors of both melanocortin receptor sensitivity and oxytocin system responsiveness.

Kisspeptin Emerging combination for comprehensive HPG axis and central desire optimization. Kisspeptin drives LH and downstream testosterone while PT-141 activates the central arousal pathway and oxytocin handles the bonding dimension. Limited human data but mechanistically one of the most complete sexual health stacks available.

Avoid combining with MT-2 simultaneously. Avoid other vasoactive compounds without medical oversight.

SIDE EFFECTS

Nausea (PT-141) The primary dose-limiting factor for this combination. Peaks at 30 to 90 minutes post-dose. Managed by starting at the lower dose, dosing on a light stomach, and avoiding alcohol. Typically diminishes with repeated use. If nausea is significant the dose is too high rather than the compound being poorly tolerated.

Facial flushing and warmth (PT-141) Universal at therapeutic doses, transient, and considered by most experienced users as a reliable indicator of active absorption rather than an adverse effect. Lasts 30 to 60 minutes.

Emotional intensity or vulnerability (Oxytocin) Oxytocin's reduction of amygdala threat-signaling can produce unexpected emotional openness, particularly in individuals who carry significant stress, past relational trauma, or emotional guardedness. This is generally experienced positively in the right context but can feel disorienting if the user is unprepared for it or using the compound alone. Worth being aware of rather than alarmed by.

Transient blood pressure increase (PT-141) Approximately 6 to 8mmHg systolic at standard doses, self-resolving within 12 hours. Clinically relevant for cardiovascular history or antihypertensive use.

Headache Reported by roughly 10 to 15% of users, typically mild and short-lived. Hydrate well before dosing.

Hyperpigmentation Residual MC1 activity from PT-141 can deepen existing moles and freckles with frequent ongoing use. Monitor with regular dermatological review for regular users.

Nasal irritation Mild and transient. Alternate nostrils and allow a few seconds between sprays for absorption before breathing in.

Priapism Rare but documented with PT-141. Any erection lasting more than 4 hours requires immediate medical attention.

STORAGE

Refrigerate at 2 to 8°C. Use within 30 days of preparation. Store away from light. Do not freeze. Do not shake. Store upright. Label with preparation date. Both compounds are sensitive to temperature cycling; avoid repeated removal from refrigeration between uses.

DISCLAIMER

For educational purposes only and does not constitute medical advice. 

Most healing peptides work locally. They drive repair at the site of injection or in the tissue immediately surrounding it.

TB-500 works systemically. It circulates, reaches damaged tissue throughout the body, and initiates repair from the inside out by solving the problem that sits upstream of most recovery failures: getting the right cells to the injury site in the first place.

The primary mechanism is actin regulation. Actin is the structural protein that governs cell shape, movement, and division. TB-500 sequesters actin monomers and controls their availability for filament assembly, which directly controls how fast and how efficiently cells can migrate. Keratinocytes to close skin wounds. Endothelial cells to form new blood vessels. Myoblasts to repair muscle fibers. Stem cells mobilized from bone marrow to damaged tissue. All of these require cell migration, and cell migration requires actin dynamics. TB-500 is the upstream regulator of that entire process.

This is why it differs from BPC-157 in a way that matters for stacking decisions. BPC-157 upregulates growth factor receptors and drives angiogenesis and repair signaling through VEGF and GH receptor pathways. TB-500 enables the physical movement of cells to the repair zone. One compound sets the blueprint, the other does the logistics.

One important distinction needs to be made clearly before going further: TB-500, as sold in research contexts, is typically the synthetic heptapeptide fragment corresponding to amino acids 17-23 of full-length Thymosin Beta-4 (Ac-LKKTETQ), not the complete 43-amino acid protein. The human clinical trial data from RegeneRx Biopharmaceuticals was conducted using full-length Thymosin Beta-4, not this fragment. Whether the injectable fragment behaves identically to the parent molecule in humans has not been rigorously tested in clinical trials. This distinction is glossed over in most posts on this compound and it belongs in any honest discussion of the evidence.

Let's go through it.

And before we begin, if you are wondering where to get it, you can get TB-500 from here.

What It Actually Is

Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino acid peptide encoded by the TMSB4X gene. It is one of the most abundant intracellular proteins in the human body, present in virtually all tissue types except red blood cells, with highest concentrations in platelets, white blood cells, plasma, and wound fluid. When injury occurs, Tβ4 is one of the first molecules released at the damage site, which is mechanistically significant: the body already uses it as a primary wound response signal.

TB-500, as it exists in research use, is a synthetic version of the active region of Tβ4, specifically the heptapeptide fragment Ac-LKKTETQ corresponding to amino acids 17-23. This fragment was identified in doping control research on equine samples and represents the actin-binding domain of the full-length molecule. It retains the cell migration and angiogenic activity associated with the full Tβ4 sequence but may not replicate the full biological profile of the 43-amino acid parent molecule.

The full Tβ4 molecule has distinct functional regions: amino acids 1-4 govern anti-inflammatory and anti-fibrotic effects, amino acids 1-15 inhibit apoptosis, and amino acids 17-23 (the TB-500 fragment) drive angiogenesis and cell migration. Running TB-500 means you are specifically targeting the migration and angiogenesis arm of what full Tβ4 does. This is still meaningfully active pharmacology, but it is not the complete picture of the parent molecule.

TB-500 is WADA prohibited at all times under S2. Validated doping control assays for the fragment exist. Competitive athletes subject to testing should treat this as a hard stop.

How It Works

Actin Sequestration and Cell Migration: The Core Mechanism

Actin exists in two forms inside cells: G-actin (globular, monomeric, unpolymerized) and F-actin (filamentous, polymerized). The dynamic interconversion between these two forms controls cell shape, movement, and division. TB-500 binds G-actin monomers and sequesters approximately 40-50% of the total G-actin pool in most cell types, maintaining a reserve of actin monomers available for rapid mobilization when migration signals arrive.

When a cell receives signals to migrate toward an injury site, TB-500 releases its sequestered actin to profilin, which catalyzes nucleotide exchange and directs actin monomers to growing filament ends at the leading edge of the cell. This allows the cell to extend membrane protrusions, move directionally, and travel through damaged tissue to the repair zone.

The practical implication: without adequate actin dynamics, repair cells stall. They are present in the body but cannot navigate efficiently to the injury site. TB-500 solves this bottleneck.

In wound healing studies, Tβ4 stimulated keratinocyte migration up to 300% over controls within five hours at concentrations as low as 10 picograms. This is potent cell migration activity at extremely small concentrations.

Angiogenesis

TB-500 promotes endothelial cell migration, tubule formation, and stabilization of new vascular structures through VEGF upregulation and direct effects on endothelial cell behavior. The LKKTET sequence specifically contributes to angiogenic activity. Mutations in this region substantially reduce the angiogenic capacity of the molecule.

New blood vessel formation is not optional for tissue repair. Damaged tissue with inadequate blood supply cannot receive the oxygen, nutrients, and repair signals needed for recovery. Chronic injuries, particularly in tendons and ligaments with already poor vascularity, benefit most from angiogenic support.

Anti-Inflammatory Activity

TB-500 reduces expression of pro-inflammatory cytokines including TNF-alpha and IL-1beta, helping to resolve the acute inflammatory phase of healing rather than allowing it to persist into chronic inflammation. It also activates the Akt/mTOR pathway, which promotes cell survival and reduces apoptosis in damaged tissue.

NF-kB modulation is part of this anti-inflammatory profile, though the mechanism is distinct from KPV's direct NF-kB nuclear translocation blockade. TB-500 approaches the inflammatory signaling cascade from a different entry point.

Stem Cell Mobilization

TB-500 recruits progenitor cells from bone marrow to sites of injury. This stem cell mobilization component is particularly relevant for severe or chronic injuries where local cell populations have been depleted or exhausted. It is also the mechanism behind the cardiac repair data: TB-500 activates dormant epicardial progenitor stem cells following myocardial infarction, contributing to cardiomyocyte regeneration and measurable improvements in cardiac ejection fraction in animal models.

Anti-Fibrotic Activity

By inhibiting TGF-beta-driven collagen deposition, TB-500 reduces fibrosis and scar formation in healing tissue. This is mechanistically important: unregulated fibrotic response to injury produces disorganized scar tissue rather than functional regenerated tissue. TB-500 shifts the balance toward organized repair. The Ac-SDKP tetrapeptide fragment of Tβ4 specifically carries anti-fibrotic properties and inhibits hematopoietic stem cell proliferation through a complementary mechanism.

What the Research Shows

Animal and Preclinical Data

Tβ4 accelerated wound healing in multiple rodent models including normal animals, diabetic mice (db/db), and aged mice where healing is typically impaired. In a full-thickness skin defect model, Tβ4 treatment sustained high expression of VEGF and basic fibroblast growth factor, improving the matrix environment for cell proliferation and migration throughout the healing timeline.

In burn wound models, Tβ4 improved wound closure through mechanisms associated with heat shock protein 70 expression and F-actin regulation.

Cardiac data: Tβ4 significantly reduced necrotic areas in cardiac ischemia models, increased VEGF expression and superoxide dismutase activity, and improved survival rates in animals receiving 5 mg/kg twice daily. This is the most compelling single-tissue data point in the TB-500 research profile and drove RegeneRx's decision to advance into human cardiac repair trials.

Neurological: Tβ4 treatment improved functional recovery in mouse models of experimental autoimmune encephalomyelitis, attributed to neurogenesis and axonal remodeling effects.

Hepatic: Tβ4 prevented oxidative stress, inflammation, and fibrosis in ethanol- and LPS-induced liver injury models in mice, suggesting protection against toxic hepatic insult.

Human Data: Full-Length Thymosin Beta-4 (Not TB-500 Fragment)

RegeneRx Biopharmaceuticals conducted Phase 1 and Phase 2 clinical trials using full-length Thymosin Beta-4. These are the only completed human trials relevant to this compound class.

Dermal ulcer Phase 2 trials showed statistically significant wound closure improvements in venous stasis ulcers compared to placebo. The full-length molecule was well tolerated with a clean safety profile.

Cardiac repair Phase 1/2 trials demonstrated safety and tolerability in injectable full-length Tβ4 for myocardial infarction applications. Phase 2 trials were paused due to funding constraints at RegeneRx rather than safety signals. The IND filings remain active.

Ophthalmology: Tβ4 eye drops have been evaluated for dry eye and corneal wound healing in human trials, demonstrating anti-inflammatory and wound healing activity at the ocular surface.

The critical caveat stated again: all human trial data is for full-length Thymosin Beta-4, not the TB-500 fragment. Whether the fragment produces equivalent systemic effects in humans at the doses used in research protocols has not been directly studied in controlled human trials. The mechanism is plausible and the preclinical data on the fragment is compelling, but the evidence gap is real.

What It Feels Like

TB-500 is a systemic compound and the effects reflect that. Unlike BPC-157, which produces fairly rapid localized responses, TB-500 operates on a longer timeline and its effects are more diffuse.

Week 1 to 2: Reduction in background inflammation and joint discomfort is the most consistently reported early effect. Chronic low-grade soreness in previously injured areas begins to quiet down. This anti-inflammatory effect precedes the structural repair timeline.

Week 2 to 4: Recovery between training sessions improves. Stalled or chronic injuries that have not responded to other interventions begin to show signs of progress. Range of motion in affected joints often improves as inflammatory load decreases and tissue begins remodeling.

Week 4 to 8: Structural changes in previously damaged tissue become more apparent. Tendon and ligament resilience under load improves. People running it alongside a training program report the ability to handle training stress that previously aggravated the injury site.

Systemic effects beyond the primary injury: skin quality and wound healing speed improve across the body, not just at the target injury site. This is consistent with TB-500's systemic mechanism of action rather than localized depot delivery.

The timeline for meaningful structural repair is longer than the timeline for inflammation reduction. Most people notice the anti-inflammatory effects in the first few weeks but need a full 8 to 12 week cycle to see real tissue-level improvement.

Dosing

Research use only. Not FDA-approved. WADA prohibited.

Route: subcutaneous injection. Intramuscular injection near the affected tissue is also used in some musculoskeletal protocols, though systemic subcutaneous administration is the more common approach given TB-500's systemic mechanism.

Standard research protocol:

Loading phase (weeks 1 to 4): 5 to 10 mg per week, typically split into two injections of 2.5 to 5 mg. Loading doses are used to build tissue levels and address acute or chronic injury backlog.

Maintenance phase (weeks 5 to 10): 2 to 5 mg per week, one to two injections. Maintains tissue levels for ongoing repair signaling without the higher loading dose.

Cycle length: 8 to 12 weeks total. Off-cycle break of 4 to 8 weeks before repeating.

Typical reconstitution: add 2.0 mL bacteriostatic water to a 5 mg vial, giving 2.5 mg/mL. On a U-100 insulin syringe, 1 unit delivers 25 mcg. A 2.5 mg dose equals 100 units (1.0 mL). Adjust syringe size accordingly for these larger volumes, a standard insulin syringe may not be practical for the loading phase doses.

Storage: lyophilized at -20°C. Reconstituted at 4°C.

Side Effects and Safety

The safety profile across RegeneRx's human trials with full-length Tβ4 was consistently clean. No serious adverse events were attributed to the compound across Phase 1 and Phase 2 trials.

Injection site reactions: mild redness, localized swelling, or discomfort at the injection site are the most commonly reported effects in research community protocols. These are typically mild and resolve within 24 to 48 hours.

Fatigue or tiredness has been reported by some users in the first week or two, possibly related to increased metabolic demand as systemic repair processes ramp up. Self-resolving.

Cancer: TB-500 promotes angiogenesis and cell migration, both of which are processes that tumors also exploit for growth and spread. This is the primary theoretical concern with the compound. No direct evidence establishes that TB-500 promotes tumor development in cancer-free individuals, but the mechanism warrants clear contraindication in anyone with active malignancy, suspected malignancy, or recent cancer history. This is not a minor caveat. It is the most significant safety consideration for this compound.

No hormonal disruption. No HPG axis suppression. No cortisol elevation. TB-500 is not an endocrine compound.

Long-term safety data in humans specifically for the TB-500 fragment does not exist in controlled trials.

TB-500 vs. BPC-157: Why Both Matter

This is the most common comparison question in the healing peptide space and it deserves a direct answer.

TB-500 and BPC-157 are not redundant. They target different rate-limiting steps in the same repair process.

BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, activates JAK-2/STAT signaling, drives angiogenesis through VEGFR2, and modulates nitric oxide pathways. It is primarily a growth factor signaling compound. It tells the tissue to repair itself and recruits vascular support through receptor-mediated signaling.

TB-500 solves the cell migration problem. It ensures the cells doing the repair can actually get to the site, move through damaged tissue efficiently, and form the new vasculature that makes sustained repair possible. It also provides systemic anti-inflammatory and anti-fibrotic coverage that BPC-157 does not specifically address.

Running both together means you are telling the tissue to repair (BPC-157) while simultaneously ensuring the cellular logistics needed to execute that repair are optimized (TB-500). The KLOW blend contains both for this reason.

There is no controlled human trial demonstrating additive or synergistic benefit from the combination. The rationale is mechanistic complementarity, which is a reasonable basis for stacking but is not the same as demonstrated combined efficacy.

Where To Find Trusted Research Suppliers

For vetted suppliers trusted by this community, see our USP Trusted Vendors List

Community

If you have run TB-500, post the actual data:

• What injury or condition were you targeting?
• Did you run a loading protocol or go straight to maintenance dosing?
• How long before you noticed meaningful improvement in the target area?
• Did you stack it with BPC-157 and if so did the combination feel different from either alone?

I have answered this question tons of times in the comments of one of my other posts, I thought it would be a good idea to give this question a full post to clear it up.

The three solutions and what they actually are

Sterile water is pure H₂O. Nothing added. Sterilized to eliminate microbial contamination, zero preservatives.

BAC water is sterile water with 0.9% benzyl alcohol added. That preservative inhibits bacterial growth over time, which is why it's the standard for multi-use vials.

Saline is sterile water with 0.9% sodium chloride added. Isotonic, meaning it matches the salt concentration of your body's fluids.

Nasal comfort ranked

Saline > Sterile water > BAC water

Saline barely registers. Sterile water stings slightly. BAC water burns a little because benzyl alcohol is an irritant at mucosal surfaces. All three work. Comfort is the tradeoff.

Shelf life after reconstitution

• BAC water: 28-30 days refrigerated (2-8°C). Standard for most peptides.
• Sterile water: 5-7 days. Single or fast-use vials usually. In a clinical setting, single time use.
• Saline: 7-14 days. The salt doesn't protect against bacterial growth the way benzyl alcohol does.

Some people run refrigerated saline-based nasal or peptide solutions 2–4 weeks, but that is usually informal practice, not the conservative sterility standard.

When saline may be chosen over BAC water, Saline may be preferred when:

• Compound is sensitive to benzyl alcohol
• User is allergic or sensitive to benzyl alcohol
• Intranasal or specialty formulations need isotonicity

****NOW WITH ALL THAT BEING SAID. This is me telling you my experience and not telling you what to do. I have personally used saline reconstituted solutions for injection and nasal for up to 30 days and everything was fine. I have used BAC water only reconstituted Reta that was 3 months old as well. I kept my vials clean, sterile, swabbed with alcohol before every injection. Im clean with it lol. As you should be as well. ****

Where to get your supplies

Sterile water - Search "sterile water for injection 10mL" - Comes in single use vials, cheap, widely available. Pick up a box and you're set for months.

BAC water - Search "bacteriostatic water 10mL" - Comes in multi-dose vials.

Saline - Search "sodium chloride 0.9% sterile saline 10mL" - Same deal as sterile water, single use vials, grab a box.

Nasal spray bottles - Search "10mL nasal spray bottle empty sterile"

What about mixing BAC water and saline?

Simple. Instead of reconstituting with sterile water, you use BAC water directly in the vial. Add 2 mL BAC water to your peptide powder, swirl gently until dissolved. Now draw out that full 2 mL reconstituted solution and inject it into a spray bottle that already has 2 mL saline sitting in it. Total volume is 4 mL. Done.

What you end up with is a solution that has the preservation of BAC water protecting the peptide, and the isotonic comfort of saline making up the other half of the bottle. Every spray delivers a solution that sits closer to what your nasal tissue actually wants to feel.

The tradeoff worth knowing: the benzyl alcohol concentration in the final bottle is roughly half of what it would be in a straight BAC water build, around 0.45% instead of 0.9%. Still works, benzyl alcohol is effective down to around 0.5%, but you're closer to the lower bound. Treat the window as 28 days and don't push it.

Best suited for daily-use peptides like Semax and Selank where you're spraying every day and comfort adds up. For on-demand compounds like PT-141 and MT-II where the bottle sits untouched for days at a time, reconstitute with BAC water and dilute with BAC water. You want full preservative strength when usage is unpredictable.

Building the spray bottle

Same process every time. 2 mL diluent into the bottle first, then 2 mL reconstituted peptide solution on top. Total volume always 4 mL. One spray delivers 0.1 mL.

Universal formula: total mg divided by total mL equals mg/mL. Multiply by 0.1 to get mg per spray. Works for any peptide, any volume.

Semax: 5 mg vial (125 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 2.5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL saline. Final concentration 1.25 mg/mL.

Typical daily dose: 200-400 mcg, 2-4 sprays split between nostrils.

At 200 mcg/day (20 days of solution):

• Sterile water or saline only: exceeds the window, stability limits before the bottle is empty.
• BAC water only: covered at 28-30 days.
• BAC + saline: covered, smoother delivery, stay conservative on the window.

At 400 mcg/day (10 days of solution):

• Sterile water or saline only: past the safe window.
• BAC water or BAC + saline: covered comfortably.

Semax: 10 mg vial (250 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL saline. Final concentration 2.5 mg/mL.

At 200 mcg/day (40 days of solution):

• Sterile water or saline only: not appropriate.
• BAC water only: exceeds the window. Split into two builds or dose higher.
• BAC + saline: same, split the build.

At 400 mcg/day (20 days of solution):

• Sterile water or saline only: not appropriate.
• BAC water or BAC + saline: covered.

Selank: 5 mg vial (125 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 2.5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL saline. Final concentration 1.25 mg/mL.

Typical daily dose: 250-750 mcg, 2-6 sprays per day.

At 250 mcg/day (20 days of solution):

• Sterile water or saline only: exceeds window.
• BAC water or BAC + saline: covered.

At 500 mcg/day (10 days of solution):

• Sterile water or saline only: borderline, high risk.
• BAC water or BAC + saline: covered.

At 750 mcg/day (7 days of solution):

• Sterile water or saline only: right at the edge, still risky.
• BAC water or BAC + saline: covered. At this dose frequency the comfort benefit of the saline split is most noticeable.

Selank: 10 mg vial (250 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL saline. Final concentration 2.5 mg/mL.

At 250 mcg/day (40 days of solution):

• Sterile water or saline only: not appropriate.
• BAC water or BAC + saline: exceeds window. Split the build.

At 500 mcg/day (20 days of solution):

• Sterile water or saline only: not appropriate.
• BAC water or BAC + saline: covered.

At 750 mcg/day (13 days of solution):

• Sterile water or saline only: exceeds window.
• BAC water or BAC + saline: covered.

PT-141: 10 mg vial (250 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL BAC water. Final concentration 2.5 mg/mL.

Dosing: 0.5-2 mg per use, 2-8 sprays. On demand, not daily.

Sterile water and saline are not realistic options here. Usage is irregular, the bottle sits between doses. Reconstitute with BAC water, dilute with BAC water. Full preservative strength only.

Build fresh every 28-30 days. At 2x per week you'll use roughly 8 doses per build, well matched to the window.

Hits faster nasally than subQ for most people. Start at 0.5 mg. Nausea is common and the nasal route amplifies it.

Melanotan II: 10 mg vial (250 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL BAC water. Final concentration 2.5 mg/mL.

Dosing: 500 mcg-1 mg per use, 2-4 sprays. On demand.

Same rule as PT-141. BAC water only, both reconstitution and dilution. On-demand compounds with irregular use need full preservative strength. Build fresh every 28-30 days.

Start conservative. Nausea and facial flushing are common, especially early. Dose in the evening until you know how you respond.

My Final Notes

Run the math before you build, not after. Total volume divided by daily usage tells you exactly how long the bottle needs to last. Match your diluent to that number.

Sterile water or saline only: fast-use builds finished within a 7-14 days. BAC water only: on-demand compounds, anything unpredictable. BAC water reconstitution into saline: daily peptides where you want full shelf life with better nasal comfort.

Alright! I’ve got about 7 peptides that I picked up and started testing around two months ago. I’ve been slowly adding them in so I can write reports on them and actually know what’s doing what. I’ll make another post on all the peptides I’m testing, but for this one specifically, we’re talking about DSIP.

If I had to describe my experience so far in one sentence, it’s this: it’s like Inception in a bottle. You have dreams that are three layers deep lol. They’re the most vivid dreams possible. I’ve had a couple lucid dreams, and when you wake up, you’re like, holy shit… was that real or was that a dream? I cannot express enough how crazy my dreams have been.

I’ve definitely noticed I feel a lot more well-rested when I wake up. I read a lot about this peptide before taking it and did a ton of research, and what I found was people were starting way too low/not feeling anything. And for something like this, I just said screw it and went out of the gate at 500 mcg daily. The “starting point” is supposed to be 100–300 mcg, but I personally didn’t want to go through that and wait, so I jumped in at 500 mcg—and that was perfect.

I’ve now been on it for about three weeks, still at the same dose, and it’s still just as effective, so there hasn’t been any need to increase it. I’m not gonna lie—I did bump it one day just for shits and giggles up to 750 mcg, and honestly that dream was a little too real, so I backed down to 500 mcg lol.

And let me tell you, it’s nothing like melatonin. I absolutely hate melatonin. Every time I take it, it doesn’t make me sleepy, but I’ll fall asleep for three hours and then I’m wide awake the rest of the night. Worst sleep aid for me personally.

So far, ranking my favorite lifestyle peptides:
#1 Reta, #2 Melanotan-2, #3 DSIP.
I’m obsessed with sleep. I think it’s the most underrated thing in today’s world. With all the biohacking and grind mindset, everybody thinks they need to work insane hours and sleep five hours, which makes zero sense. My entire day is ruined if I don’t get at least six hours.

So all in all, I’d say this one is worth giving a shot—pun intended. I’m curious: if you’ve run this peptide before, what was your experience? And did you start with 100 mcg, or were you aggressive with it like me and jumped to 500 mcg?

Let me know in the comments below.